Ophthalmology – Herpes Simplex Keratitis

Basics

Description

Herpes simplex keratitis (HSK) is a corneal infection caused most commonly by herpes simplex virus type 1 (HSV-1). Primary HSV infection usually occurs in childhood and may be mild or even clinically inapparent. After the initial infection, the virus becomes latent within sensory ganglia, particularly the trigeminal ganglion, where it can remain dormant for years before reactivation.

Reactivation can produce several forms of ocular disease. Superficial epithelial infection may begin with conjunctival inflammation, punctate epithelial keratitis, or small corneal vesicles that evolve into the classic dendritic epithelial ulcer. A dendritic lesion can enlarge and become a broader geographic ulcer.

Deeper forms of HSV keratitis involve the corneal stroma or endothelium. Stromal disease may be immune-mediated, necrotizing, or associated with anterior uveitis. Disciform keratitis, now generally considered a form of HSV endotheliitis, produces localized stromal edema because of inflammation involving the corneal endothelium.

Repeated episodes can lead to corneal scarring, thinning, irregular astigmatism, reduced corneal sensation, and permanent visual loss. Rarely, severe stromal disease can result in perforation.

Epidemiology

HSV is one of the most important infectious causes of corneal blindness worldwide.

Primary systemic HSV-1 infection is very common, but only a minority of infected individuals develop ocular disease.

Herpetic keratitis may occur as an initial episode or as recurrent disease. Recurrences are particularly important because repeated stromal inflammation is a major cause of permanent corneal scarring and visual impairment.

Risk Factors

Reactivation has historically been associated with events such as febrile illness, upper respiratory infection, ocular trauma, psychological stress, menstruation, and contact lens wear, although not all proposed triggers have been consistently proven.

Prior episodes of ocular HSV are the strongest clinical predictor of future recurrence.

Genetics

Genetic susceptibility probably contributes to the likelihood and severity of HSV ocular disease, but no single genetic pattern explains most cases.

General Prevention

Long-term oral antiviral prophylaxis can reduce recurrent ocular HSV in selected patients, particularly those with previous recurrent stromal keratitis or multiple clinically significant episodes.

Pathophysiology

After primary infection, HSV travels along sensory nerves and establishes latency within the trigeminal ganglion.

During reactivation, infectious virus can travel back down sensory axons toward the eye and produce epithelial disease.

Epithelial keratitis is caused primarily by active viral replication within corneal epithelial cells.

Stromal and endothelial disease have a more complicated pathogenesis. They may involve a combination of viral antigen, persistent or recurrent viral activity, and a host immune response that damages corneal tissue.

Repeated inflammation can cause progressive stromal scarring and loss of corneal transparency.

Commonly Associated Conditions

Patients with ocular HSV may have a history of herpes labialis or vesicular lesions around the mouth, nose, eyelids, or periocular skin.

However, the absence of a history of cold sores does not exclude ocular HSV.

Diagnosis

History

Patients may report ocular irritation, foreign-body sensation, pain, redness, photophobia, tearing, or blurred vision.

Blurred vision is more likely when the lesion involves the visual axis or when stromal edema is present.

A previous episode of unilateral red eye, dendritic keratitis, unexplained corneal scarring, or recurrent herpetic disease can be diagnostically helpful.

Physical Examination

A careful slit-lamp examination is essential.

Vital dyes such as fluorescein and, when appropriate, rose bengal or lissamine green can help delineate epithelial lesions.

Corneal sensation should also be assessed because reduced corneal sensitivity is common after recurrent HSV disease.

Epithelial Herpes Simplex Keratitis

The classic lesion is a dendritic ulcer.

It consists of a branching epithelial defect with terminal bulbs.

The central ulcerated portion stains with fluorescein, while the swollen epithelial borders may stain with rose bengal or lissamine green.

Dendrites can enlarge and merge into a broader irregular geographic epithelial ulcer, particularly in patients who have received inappropriate topical corticosteroids.

Stromal Herpes Simplex Keratitis

Stromal disease may be non-necrotizing immune stromal keratitis or necrotizing stromal keratitis.

Immune stromal disease causes stromal haze, edema, and sometimes vascularization without a major epithelial defect.

Necrotizing stromal keratitis is more severe and may involve active viral infection, stromal ulceration, marked inflammation, thinning, and risk of perforation.

HSV Endotheliitis / Disciform Keratitis

HSV can produce endothelial inflammation resulting in disc-shaped stromal edema, keratic precipitates, and sometimes anterior chamber inflammation.

This has historically been termed disciform keratitis.

The corneal epithelium may initially remain intact.

HSV Anterior Uveitis

HSV can also cause anterior uveitis.

Possible findings include keratic precipitates, anterior chamber cells and flare, iris atrophy, and elevated intraocular pressure.

The combination of unilateral anterior uveitis, increased IOP, and sectoral iris atrophy should raise suspicion for herpetic disease.

Diagnostic Tests and Interpretation

Laboratory Testing

Typical dendritic epithelial keratitis is usually diagnosed clinically and generally does not require laboratory confirmation.

When the presentation is atypical, recurrent, severe, or involves deeper structures, laboratory testing can be useful.

PCR of corneal, aqueous, or other ocular samples may detect HSV DNA and can help distinguish HSV from VZV, CMV, and other causes.

Viral culture is less commonly required.

Imaging

Routine imaging is not generally necessary for uncomplicated HSV keratitis.

Anterior-segment photography or OCT may occasionally be useful for documenting severe or chronic corneal disease.

Pathological Findings

Corneal biopsy is rarely necessary.

When tissue is examined, findings vary depending on whether disease involves the epithelium, stroma, or endothelium and may include epithelial necrosis, inflammatory infiltration, stromal scarring, and viral cytopathic changes.

Differential Diagnosis

Important differential diagnoses include herpes zoster keratitis, Acanthamoeba keratitis, fungal keratitis, bacterial keratitis, Epstein-Barr-associated disease, neurotrophic epithelial defects, and other causes of persistent or atypical corneal ulceration.

HSV dendrites should also be distinguished from pseudodendrites, particularly those caused by herpes zoster.

Treatment

Treatment depends on which corneal layer is involved.

Epithelial Keratitis

Active epithelial HSV disease is treated with antiviral therapy.

Topical options include ganciclovir gel or, in some settings, trifluridine.

Oral antivirals such as acyclovir or valacyclovir are also effective and are often used because they are convenient and avoid topical epithelial toxicity.

Topical corticosteroids should not be used for active epithelial dendritic or geographic keratitis unless there is a specific specialist-directed indication with adequate antiviral coverage.

Stromal Keratitis

Immune-mediated stromal keratitis is treated with topical corticosteroids combined with antiviral coverage.

Steroids are tapered slowly according to clinical response because rapid withdrawal can precipitate recurrence.

Oral antiviral therapy is often used during steroid treatment.

Necrotizing Stromal Keratitis

Necrotizing disease requires aggressive antiviral therapy and specialist management.

Topical corticosteroids may be used cautiously when indicated, but only with adequate antiviral coverage because active viral replication may be present.

Endotheliitis and Uveitis

HSV endotheliitis and anterior uveitis are commonly treated with topical corticosteroids plus systemic or topical antiviral therapy.

Elevated intraocular pressure should be treated appropriately.

Because prolonged steroid therapy may be necessary in some cases, careful monitoring for glaucoma and cataract is required.

Long-Term Antiviral Prophylaxis

Suppressive oral antiviral therapy can be considered in patients with recurrent disease, especially those with recurrent stromal keratitis, previous corneal transplantation for HSV, or frequent vision-threatening recurrences.

Long-term prophylaxis reduces the risk of recurrent ocular HSV while therapy is continued.

Surgery

Severe corneal scarring, irregularity, thinning, or perforation may eventually require surgical treatment.

Penetrating keratoplasty or selected lamellar corneal transplantation procedures may be used for visually significant scarring or structural compromise.

Active inflammation should ideally be controlled before elective corneal transplantation because recurrent HSV can affect the graft.

Antiviral prophylaxis is commonly used around and after keratoplasty in patients with prior HSV disease.

Follow-Up

Patients with active dendritic keratitis require serial slit-lamp examinations until the epithelial defect has healed.

Stromal keratitis, endotheliitis, and uveitis usually require longer and closer follow-up, particularly during corticosteroid tapering.

Patients with recurrent disease may require lifelong intermittent ophthalmic monitoring.

Patient Monitoring

Monitoring should include visual acuity, corneal epithelial integrity, stromal inflammation, corneal thickness, corneal sensation, intraocular pressure, and anterior chamber inflammation.

Patients receiving topical corticosteroids should be monitored for steroid-related ocular hypertension and cataract.

Patient Education

Patients should understand that HSV remains latent in the nervous system and may recur even years later.

They should be instructed not to self-treat recurrent red eye with leftover steroid drops because steroids can worsen active epithelial HSV dramatically.

Any recurrence of unilateral redness, pain, photophobia, or decreased vision should prompt an early ophthalmic examination.

Pediatric Considerations

Infants and children can develop ocular HSV after maternal antibodies decline.

Because herpetic epithelial disease may worsen rapidly with corticosteroids, topical steroids should not be used empirically for an unexplained red eye in a child without appropriate ophthalmic examination.

Children also require careful monitoring for amblyopia if corneal scarring or irregular astigmatism develops.

Prognosis

The prognosis is generally good for an initial episode of epithelial dendritic keratitis when promptly treated with antiviral therapy.

The prognosis becomes more guarded with recurrent stromal keratitis, endotheliitis, corneal neovascularization, thinning, or scarring.

Repeated stromal episodes are the major cause of permanent visual morbidity.

Complications

Complications include recurrent epithelial keratitis, neurotrophic keratopathy, stromal scarring, corneal neovascularization, irregular astigmatism, corneal thinning, secondary glaucoma, cataract, and rarely corneal perforation.

The greatest risk of substantial long-term vision loss comes from recurrent stromal HSV disease rather than from a single uncomplicated dendritic epithelial episode.

Ophthalmology – Hemangioma in Children

Basics

Description

Infantile hemangioma is a benign vascular tumor of infancy that can involve the eyelids, orbit, or surrounding periorbital tissues. It characteristically undergoes a phase of rapid postnatal growth followed by gradual spontaneous involution.

The main ophthalmic concern is not the tumor itself but its ability to interfere with visual development. A periocular hemangioma can obstruct the visual axis, induce astigmatism or anisometropia, produce ptosis, or cause proptosis, all of which can lead to amblyopia.

Epidemiology

Infantile hemangiomas occur in approximately 1–2.6% of newborns. They are among the most common benign vascular tumors of infancy.

Most lesions become apparent during the first few weeks of life and enlarge rapidly during the first several months.

Risk Factors

Important risk factors include female sex, Caucasian race, prematurity, and a positive family history. An association with chorionic villus sampling has also been reported.

Genetics

Most infantile hemangiomas are sporadic and have no clear hereditary basis.

Rare familial forms have been reported with an autosomal dominant pattern with variable expression, including linkage to chromosome 5q31–33.

Genetic counseling may be appropriate in clearly familial cases or when the child has features of a syndromic vascular disorder.

Pathophysiology

During the proliferative phase, hemangiomas show increased endothelial cell growth and high expression of vascular endothelial growth factor (VEGF) and other proangiogenic factors.

As the lesion enters its involutional phase, angiogenic signaling decreases and endothelial cells undergo apoptosis, allowing the vascular tumor to progressively regress.

Etiology

Infantile hemangiomas represent a benign proliferation of blood vessels. They are often described as hamartomatous vascular growths, although modern classification considers infantile hemangioma a true benign vascular tumor with a characteristic growth and involution cycle.

Commonly Associated Conditions

Large or segmental facial hemangiomas may be associated with PHACE syndrome, which includes posterior fossa abnormalities, large facial hemangiomas, arterial anomalies, cardiac abnormalities including coarctation of the aorta, eye abnormalities, and sternal or ventral developmental defects.

Very large vascular tumors associated with thrombocytopenia and consumptive coagulopathy require urgent evaluation. Importantly, classic Kasabach-Merritt phenomenon is generally associated with kaposiform hemangioendothelioma or tufted angioma rather than typical infantile hemangioma.

Other vascular or developmental syndromes that may enter the differential include Maffucci syndrome and Klippel-Trenaunay syndrome.

Diagnosis

History

The characteristic history is of a vascular lesion that appears shortly after birth and undergoes rapid growth during the first several months of life.

A lesion may initially appear as a small red macule or may not be obvious at birth.

Growth is usually most rapid during infancy. Spontaneous involution begins later, often during the second year of life, and may continue for several years.

Parents should be asked about feeding or breathing difficulty, noisy breathing, skin lesions elsewhere on the body, bleeding, bruising, and any change in fixation behavior.

Physical Examination

A complete ocular examination is required.

Superficial lesions are typically bright red, whereas deeper subcutaneous lesions may have a bluish-purple appearance.

Hemangiomas are generally compressible and may blanch with pressure. They may enlarge or become more violaceous during crying, straining, or dependent positioning.

The size and location of the lesion should be documented, preferably with serial photography.

Particular attention should be paid to whether the lesion obstructs the visual axis, induces ptosis, or causes an abnormal head posture.

Visual Development

Cycloplegic refraction is important because periocular hemangiomas can induce significant astigmatism, anisometropia, or myopic shift.

Even a lesion that does not directly cover the pupil can produce amblyopia through corneal distortion.

Fixation preference, ocular alignment, and age-appropriate visual acuity should therefore be monitored closely.

Orbital Involvement

The examination should assess for proptosis, globe displacement, optic nerve compromise, restricted ocular motility, or fullness of the temporal fossa.

An afferent pupillary defect or reduced vision raises concern for optic nerve compression or another serious orbital complication.

Diagnostic Tests and Interpretation

Laboratory Testing

No laboratory testing is necessary for a typical isolated lesion.

A complete blood count with platelet count may be appropriate in a child with a very large vascular tumor, petechiae, bleeding, or concern for a consumptive coagulopathy.

Ultrasound

Ultrasonography can demonstrate a compressible vascular lesion with internal blood flow.

Doppler imaging can help confirm the vascular nature of the mass.

MRI

MRI is preferred when deeper orbital involvement, extensive facial disease, PHACE syndrome, or possible intracranial extension is suspected.

It provides excellent visualization of the lesion’s extent and relationship to the orbit, brain, and vascular structures without ionizing radiation.

CT

CT may demonstrate associated bone changes but is generally avoided when MRI can provide the necessary information because of radiation exposure in infants.

Biopsy

Biopsy is rarely needed when the clinical appearance is typical.

It may be considered when an atypical rapidly growing orbital mass raises concern for rhabdomyosarcoma or another neoplasm.

Pathological Findings

During the proliferative phase, lesions show dense proliferation of small capillary-sized vessels lined by plump endothelial cells, often accompanied by pericytes and other stromal cells.

During involution, endothelial proliferation declines and vascular tissue is progressively replaced by fibrofatty tissue.

Differential Diagnosis

Important differential diagnoses include rhabdomyosarcoma, lymphatic malformation, venous malformation, congenital vascular malformation, port-wine stain, arteriovenous malformation, neuroblastoma metastasis, encephalocele, and dacryocystocele.

A port-wine stain differs from an infantile hemangioma because it is a capillary malformation present at birth that generally grows proportionally with the child rather than undergoing a rapid proliferative phase followed by spontaneous involution.

Treatment

Many periocular hemangiomas can be observed if they do not threaten vision, cause significant disfigurement, ulcerate, or produce other functional complications.

Treatment becomes necessary when there is risk of amblyopia, visual axis obstruction, rapidly progressive orbital disease, significant astigmatism or anisometropia, optic nerve compression, ulceration, or major cosmetic deformity.

Amblyopia Management

Amblyopia should be treated aggressively when present.

Management may include full spectacle correction, patching of the better-seeing eye, or atropine penalization, depending on the child’s age and the degree of visual asymmetry.

Correction of refractive error is essential even when tumor-directed therapy is being used.

Beta-Blocker Therapy

Propranolol is now the standard first-line systemic treatment for most vision-threatening infantile hemangiomas.

It can produce rapid softening, color change, and shrinkage of the lesion.

Treatment is usually coordinated with pediatrics or another clinician experienced in infantile hemangioma therapy because propranolol can cause bradycardia, hypotension, bronchospasm, and hypoglycemia, particularly in young infants.

Dosing and initiation protocols vary according to age, weight, comorbidities, and local practice.

Contraindications or important precautions include significant bronchospastic disease, certain cardiac abnormalities, and some cerebrovascular abnormalities, particularly in patients being evaluated for PHACE syndrome.

Topical Timolol

Topical timolol may be useful for selected small, superficial periocular hemangiomas.

Because systemic absorption can occur, especially in infants, it should still be used with appropriate caution and monitoring.

Deep orbital lesions generally require systemic rather than topical therapy.

Corticosteroids

Systemic corticosteroids were historically the principal treatment before the widespread use of propranolol.

They may still be considered when beta-blockers are contraindicated or ineffective.

Potential complications of prolonged systemic corticosteroid therapy include growth suppression, adrenal suppression, immunosuppression, hypertension, and Cushingoid changes.

Intralesional corticosteroid injection is now used much less often because of serious potential complications, including retinal artery occlusion, skin necrosis, depigmentation, and subcutaneous fat atrophy.

Other Medical Therapies

Interferon alfa is rarely used today because of significant neurologic and systemic toxicity.

Other systemic agents may be considered for unusually aggressive or treatment-resistant vascular tumors under specialist guidance, but these are not routine first-line therapies for typical infantile hemangioma.

Laser Treatment

Laser therapy can be helpful for selected superficial residual or ulcerated lesions, particularly when treatment is directed primarily at surface components.

Pulsed dye laser is generally more relevant than older destructive laser techniques.

Laser therapy is not usually sufficient for a deep orbital hemangioma.

Surgery

Surgery is rarely required during the proliferative phase because many lesions respond well to medical therapy and later involute spontaneously.

Partial or complete excision may be considered for sight-threatening lesions resistant to medical treatment, lesions producing persistent mechanical problems, or residual deformity after involution.

Reconstructive or cosmetic surgery is often best deferred until involution has substantially completed when possible.

Referral

Urgent otolaryngology evaluation is indicated when an airway hemangioma is suspected.

Genetics evaluation is appropriate for suspected PHACE syndrome, familial disease, or other syndromic findings.

Hematology evaluation is required if there is thrombocytopenia or concern for a consumptive coagulopathy.

Neurology, neurosurgery, cardiology, or vascular anomaly specialists may be required when there is intracranial, arterial, cardiac, or extensive orbital involvement.

Inpatient Considerations

Hospitalization may be appropriate for infants with airway compromise, severe systemic disease, or significant cardiorespiratory risk during initiation of systemic beta-blocker therapy.

Whether propranolol is started as an inpatient or outpatient depends on the child’s age, medical status, treatment protocol, and local practice.

Follow-Up

Close ophthalmic follow-up is essential during the proliferative phase.

Monitoring should include visual acuity or fixation behavior, cycloplegic refraction, ocular alignment, lesion size, ptosis, globe position, and optic nerve function.

Rebound growth can occur after discontinuation of beta-blocker or corticosteroid therapy, so follow-up should continue after treatment is stopped.

Once active growth has ceased, follow-up can be adjusted according to residual refractive error, amblyopia, and cosmetic concerns.

Patient Monitoring

The two principal ophthalmic monitoring targets are vision and refraction.

Children with periocular hemangiomas are particularly vulnerable to amblyopia from astigmatism, anisometropia, ptosis, or direct visual-axis obstruction.

Psychosocial effects of a visible facial lesion should also be considered as the child grows.

Patient Education

Parents should understand that many hemangiomas eventually involute spontaneously, but lesions near the eye require closer observation because visual development can be permanently affected.

They should seek prompt medical attention for wheezing, stridor, feeding or breathing difficulty, sudden lesion enlargement, bleeding, petechiae, reduced fixation, or increasing eyelid closure.

Families should also understand that even after the lesion shrinks, refractive error and amblyopia may persist and require continued treatment.

Prognosis

The overall prognosis is very good.

Many infantile hemangiomas undergo substantial spontaneous involution during childhood.

The visual prognosis depends mainly on whether amblyopia is prevented or treated early.

Periocular hemangiomas frequently induce astigmatic or anisometropic refractive errors, and untreated refractive asymmetry can result in permanent reduction of vision.

Complications

Potential complications include amblyopia, induced astigmatism, anisometropia, ptosis, proptosis, optic nerve compression, corneal exposure, residual eyelid deformity, skin atrophy, scarring, hypopigmentation, facial asymmetry, and psychosocial distress.

The most important preventable ophthalmic complication is permanent amblyopia from untreated visual deprivation or refractive error.

Ophthalmology – Hard Exudates

Basics

Description

Hard exudates are yellow-white retinal deposits composed mainly of lipid and protein that leak from incompetent retinal, choroidal, or optic disc vessels. They usually accumulate in the outer plexiform layer of the retina, although in more severe disease they may extend into other retinal layers or even the subretinal space.

Hard exudates are not a disease themselves. They are an ophthalmoscopic sign of underlying vascular leakage, most commonly associated with retinal vascular disorders.

Epidemiology

The true incidence is difficult to quantify because hard exudates occur as a manifestation of many different ocular and systemic diseases.

Risk Factors

Important risk factors include systemic vascular conditions such as diabetes mellitus, hypertension, and dyslipidemia.

These conditions increase the likelihood of retinal vascular leakage and therefore the development of hard exudates.

General Prevention

Good control of blood glucose, blood pressure, and serum lipid levels reduces the risk and severity of several diseases associated with hard exudates.

These include diabetic retinopathy, hypertensive retinopathy, retinal vascular occlusions, and retinal arterial macroaneurysms.

Pathophysiology

Hard exudates form when retinal or choroidal vessels become abnormally permeable.

Breakdown of the vascular barrier allows lipoproteins, serum proteins, and fluid to escape into the surrounding retinal tissue.

The fluid component may eventually be resorbed, while the lipid-rich material remains behind as visible yellow-white deposits.

For this reason, hard exudates are commonly associated with retinal or macular edema.

Etiology

A wide variety of retinal vascular and inflammatory disorders can produce hard exudates.

Common causes include diabetic retinopathy, hypertensive retinopathy, retinal vein occlusion, retinal arterial macroaneurysm, radiation retinopathy, Coats disease, retinal capillary hemangioma, neuroretinitis, and choroidal neovascularization, including that associated with age-related macular degeneration.

Commonly Associated Conditions

Macular edema is one of the most important associated findings.

When hard exudates are present near or within the fovea, vision may be significantly reduced.

Diagnosis

History

Patients may be asymptomatic if the deposits are outside the macula.

When the macula is involved, they may complain of blurred or decreased central vision.

A detailed medical history should assess for diabetes, hypertension, hyperlipidemia, vascular disease, previous radiation treatment, and other conditions associated with retinal vascular leakage.

Physical Examination

Dilated fundus examination reveals discrete yellow-white retinal deposits, usually most prominent in the posterior pole.

Their configuration may vary.

They may appear globular, linear, clustered, circinate, or confluent.

A circinate pattern refers to a ring or partial ring of hard exudates surrounding a leaking microaneurysm or other vascular abnormality.

When exudates form a radial pattern around the macula, a macular star may be present. This is classically associated with neuroretinitis and may also occur in severe hypertensive retinopathy.

Diagnostic Tests and Interpretation

Hard exudates are usually diagnosed clinically during fundus examination, but imaging is often useful for determining their cause and associated complications.

Optical Coherence Tomography

OCT is particularly useful for identifying and quantifying macular edema, subretinal fluid, and structural retinal changes associated with the exudates.

Hyperreflective foci corresponding to lipid deposits may also be visible.

Fluorescein Angiography

Fluorescein angiography can help identify the source of vascular leakage, such as microaneurysms, retinal neovascularization, macroaneurysms, or other abnormal vessels.

The hard exudates themselves generally do not leak; rather, the associated abnormal vessels demonstrate leakage.

Differential Diagnosis

Hard exudates should be distinguished from other yellow or white retinal lesions.

Important alternatives include cotton-wool spots, myelinated retinal nerve fibers, drusen, retinitis, chorioretinal atrophy, Hollenhorst plaques, and crystalline retinopathies.

Cotton-wool spots are typically softer, fluffier, and located in the retinal nerve fiber layer, whereas hard exudates are more sharply defined and yellow.

Drusen are located beneath the retinal pigment epithelium rather than within the neurosensory retina.

Treatment

Treatment is directed at the underlying cause of vascular leakage, not at the hard exudates themselves.

As vascular permeability and edema improve, the exudates may gradually be resorbed.

Systemic Treatment

Patients with diabetes, hypertension, or dyslipidemia require appropriate systemic control.

Improved management of these conditions can reduce further leakage and limit progression.

Diabetic Retinopathy and Diabetic Macular Edema

Diabetic retinopathy is one of the most common causes of hard exudates.

When hard exudates are associated with diabetic macular edema, treatment of the edema may include intravitreal anti-VEGF therapy, and in selected situations laser photocoagulation or intraocular corticosteroid therapy.

Successful treatment of the underlying leakage frequently results in gradual reduction of the hard exudates.

Other Causes

Retinal vein occlusion, choroidal neovascularization, retinal arterial macroaneurysm, Coats disease, and other vascular disorders should be treated according to their specific underlying pathology.

For example, anti-VEGF therapy may be appropriate for vascular leakage associated with retinal vein occlusion or choroidal neovascularization.

Surgery and Other Procedures

Surgical removal of hard exudates is rarely performed.

Historically, submacular surgery has been attempted in selected cases of massive subfoveal lipid deposition, particularly in severe diabetic disease, but this is not routine management.

Ongoing Care

Follow-up should focus on the underlying retinal disorder and the presence or progression of macular edema.

Serial fundus photography and OCT can be useful for documenting changes in exudation and retinal thickness.

Systemic vascular risk factors should also be reassessed regularly.

Prognosis

The visual prognosis depends primarily on the underlying disease and the location of the exudates.

Hard exudates outside the macula may have little effect on vision.

When they accumulate within or beneath the fovea, especially in association with chronic edema, permanent photoreceptor damage and reduced central vision may result.

Complications

The most important associated complication is macular edema.

Long-standing dense lipid deposition in the central macula may lead to permanent visual impairment even after the vascular leakage has been controlled.

In neuroretinitis, an afferent pupillary defect may occur during the acute phase, although it can improve as the underlying optic nerve inflammation resolves.

Ophthalmology – Visual Hallucinations

Basics

Description

Visual hallucinations are visual perceptions that occur without a corresponding external visual stimulus. They are not a diagnosis by themselves, but rather a symptom that may arise from ophthalmic, neurologic, metabolic, toxic, medication-related, or psychiatric conditions.

Hallucinations may be simple, such as flashes, colored lights, sparkles, geometric shapes, or patterns, or complex, such as seeing people, animals, faces, flowers, or complete scenes.

An especially important ophthalmic form is Charles Bonnet syndrome (CBS). In CBS, patients with significant visual impairment experience vivid, often complex visual hallucinations while retaining insight that the images are not real. Cognition is otherwise relatively preserved.

Epidemiology

The frequency of visual hallucinations varies considerably depending on the patient population and underlying disorder.

They are common in patients with dementia, delirium, metabolic encephalopathy, severe visual impairment, and certain neurologic disorders.

Among ophthalmic populations, visual hallucinations are particularly associated with older age and substantial reduction in visual acuity. Charles Bonnet syndrome is probably underrecognized because many patients are reluctant to report hallucinations for fear of being considered psychiatrically ill.

Risk Factors

Important risk factors include significant visual loss, advanced age, social isolation, dementia, psychiatric disease, alcohol or illicit drug use, medication exposure, and metabolic illness.

Women have been reported to experience visual hallucinations somewhat more frequently in some populations.

Pathophysiology

The mechanism depends on the underlying cause.

In patients with severe visual impairment, reduced sensory input to the visual cortex may produce a release phenomenon or deafferentation phenomenon. Normally, continuous external visual input suppresses internally generated visual imagery. When visual input is markedly reduced, previously suppressed visual cortical activity may emerge as hallucinations.

This mechanism is believed to contribute to Charles Bonnet syndrome.

In epilepsy, abnormal electrical activity affecting the occipital or temporal cortex can produce ictal visual hallucinations.

Migraine aura is related to cortical spreading depression, a wave of neuronal activation followed by suppression that commonly spreads through the visual cortex.

Hallucinogenic drugs and other toxic agents may alter serotonergic, limbic, and cortical pathways.

Etiology

Visual hallucinations can arise from several major categories of disease.

Ophthalmic Causes

Severe visual impairment from conditions such as advanced cataract, glaucoma, retinal disease, optic neuropathy, or loss of an eye can produce release hallucinations and Charles Bonnet syndrome.

Neurologic Causes

Neurologic causes include epilepsy, migraine, narcolepsy, Parkinson disease, Alzheimer disease, dementia with Lewy bodies, brainstem disease, thalamic disease, occipital or temporal lobe lesions, stroke, and other structural brain disorders.

Toxic and Metabolic Causes

Hallucinations may occur with drug intoxication, medication adverse effects, alcohol intoxication or withdrawal, metabolic encephalopathy, hypoxia, organ failure, and delirium.

Psychiatric Causes

Psychotic illnesses such as schizophrenia can include visual hallucinations, although auditory hallucinations are more typical.

Commonly Associated Conditions

Important associations include visual deprivation, dementia, Parkinson disease, dementia with Lewy bodies, delirium, delirium tremens, psychosis, substance use, medication toxicity, seizures, and migraine.

Diagnosis

History

A detailed description of the visual experience is essential.

Patients should be asked about:

• What exactly they see
• Whether the images are formed or unformed
• Whether the images move
• How long they last
• How often they occur
• Whether they affect one or both visual fields
• Whether they occur with eyes open, closed, or both
• Whether the patient knows the images are not real
• Associated headache, weakness, confusion, seizure activity, sleep disturbance, or other neurologic symptoms
• Visual impairment or recent worsening of vision
• Current medications
• Alcohol and illicit drug use
• Recent withdrawal from alcohol or other substances

Patients may avoid mentioning hallucinations unless asked directly because they fear being labeled as mentally ill.

That makes direct, nonjudgmental questioning especially important in patients with significant visual impairment or dementia.

Physical Examination

A full ophthalmic and neurologic examination is appropriate.

The eye examination should include visual acuity, pupillary responses, visual fields, ocular motility, anterior segment examination, and fundus examination.

The neurologic examination should assess mental status, cranial nerves, motor function, sensation, coordination, gait, and signs of focal neurologic disease.

Diagnostic Tests and Interpretation

Testing should be directed by the suspected cause rather than performed routinely in every patient.

Laboratory Testing

When toxic or metabolic disease is suspected, laboratory testing may include metabolic studies, toxicology testing, medication levels, and other investigations guided by the clinical presentation.

Electroencephalography

EEG may be useful when seizure activity or encephalopathy is suspected.

Brief, stereotyped, recurrent hallucinations, particularly when accompanied by altered awareness or other seizure manifestations, increase suspicion for an epileptic cause.

Neuroimaging

MRI of the brain is appropriate when a structural brainstem, thalamic, temporal, or occipital lesion is suspected.

Acute presentations may require urgent neuroimaging depending on associated neurologic findings.

Differential Diagnosis

Visual hallucinations must be distinguished from several related phenomena.

Delusions

A delusion is a fixed false belief that the patient believes to be true. It is not a sensory perception.

Confabulation

Confabulation refers to fabricated or distorted memories, often occurring in patients with memory impairment.

Visual Illusions

An illusion is a distorted perception of something that is actually present.

Examples include metamorphopsia, polyopia, palinopsia, or misinterpretation of real objects.

Hallucinations

A hallucination occurs when a person sees something without any corresponding external object.

Simple Visual Hallucinations

Simple hallucinations consist of elementary visual phenomena such as:

flashes, sparkles, colored lights, geometric shapes, patterns, halos, or phosphenes.

They are more often associated with occipital cortex dysfunction, migraine, retinal disease, or seizure activity.

Complex Visual Hallucinations

Complex hallucinations include formed images such as:

people, animals, faces, buildings, flowers, or complete scenes.

They may occur with Charles Bonnet syndrome, temporal lobe disorders, dementia, delirium, or brainstem disease.

Charles Bonnet Syndrome

Charles Bonnet syndrome consists of recurrent, often vivid and detailed visual hallucinations occurring in a person with significant visual impairment but without primary psychosis or major cognitive impairment.

Patients typically retain insight and recognize that the images are not actually present.

The hallucinations are often nonthreatening and may include people, animals, buildings, patterns, or scenery.

CBS is associated with a wide range of causes of reduced vision, including macular degeneration, glaucoma, cataract, diabetic eye disease, retinal degeneration, and optic neuropathy.

Reassurance is especially important because many patients fear that hallucinations indicate dementia or psychiatric illness.

Ictal Hallucinations

Visual hallucinations caused by seizures tend to be brief, stereotyped, and recurrent.

Occipital seizures usually produce simple unformed visual phenomena, whereas temporal lobe seizure activity is more likely to produce complex formed images.

Peduncular Hallucinosis

Peduncular hallucinosis consists of vivid, colorful, often highly detailed visual hallucinations associated with lesions involving the midbrain, pons, or thalamus.

Patients may maintain insight.

The mechanism is thought to involve disruption of pathways regulating visual sensory processing and arousal.

Migraine Aura

Migraine aura frequently causes transient visual phenomena such as:

flashing lights, scintillating scotomas, zigzag lines, fortification patterns, or expanding areas of visual disturbance.

These phenomena usually evolve over minutes rather than appearing instantaneously.

Alice in Wonderland Syndrome

Alice in Wonderland syndrome is a rare perceptual disturbance often associated with migraine, particularly in children.

Patients may experience metamorphopsia, altered body image, changes in perceived object size, or distortion of spatial relationships and perspective.

Hypnagogic Hallucinations

Hypnagogic hallucinations occur while a person is falling asleep.

They can be vivid and dreamlike and are particularly associated with narcolepsy, although they can occur in otherwise healthy individuals.

Dementia-Related Hallucinations

Visual hallucinations are common in several neurodegenerative disorders.

They are especially characteristic of dementia with Lewy bodies, where recurrent detailed visual hallucinations may occur together with progressive cognitive impairment, fluctuating attention, parkinsonism, and REM sleep behavior disorder.

Patients with Lewy body dementia can be highly sensitive to antipsychotic medications, an important management consideration.

Visual hallucinations also occur in Parkinson disease and Alzheimer disease.

Pediatric Considerations

In children, possible causes include seizures, migraine, sleep disorders, medication effects, substance exposure, psychiatric disease, and night terrors.

Alice in Wonderland syndrome is particularly associated with childhood migraine.

A careful neurologic and medication history is important.

Geriatric Considerations

Older adults may experience visual hallucinations because of visual impairment, dementia, delirium, medication toxicity, Parkinson disease, or Lewy body dementia.

Seeing people, animals, or detailed scenes is particularly common in both Charles Bonnet syndrome and dementia-associated hallucinations.

Distinguishing between these conditions requires assessment of cognition, insight, visual function, and neurologic status.

Treatment

Treatment depends entirely on the underlying cause.

There is no single medication appropriate for all visual hallucinations.

Charles Bonnet Syndrome Treatment

The main treatments for CBS are reassurance and optimization of vision.

Patients should be told that the hallucinations can occur as a consequence of visual deprivation and do not by themselves imply psychosis or dementia.

Correctable causes of visual impairment should be treated when possible.

Improving environmental lighting, increasing social engagement, and changing visual fixation or blinking may sometimes interrupt episodes.

Medication is rarely required unless hallucinations are persistent and severely distressing.

Seizure-Related Hallucinations

Hallucinations caused by epilepsy should be treated with appropriate antiseizure therapy under neurologic supervision.

Migraine

Migraine-associated visual phenomena are treated according to standard migraine management when attacks are frequent or disabling.

Delirium and Metabolic Disease

When hallucinations occur in delirium or metabolic encephalopathy, the priority is correction of the underlying medical abnormality.

Potential causes include infection, electrolyte disturbance, organ failure, hypoxia, medication toxicity, or withdrawal states.

Psychiatric Disease

Antipsychotic treatment may be appropriate when hallucinations arise from psychotic illness, severe agitation, or certain dementia syndromes.

Medication choice must be individualized according to the patient’s diagnosis, previous treatment response, comorbidities, potential drug interactions, and adverse-effect profile.

Dementia With Lewy Bodies

Mild hallucinations that are not distressing may require no drug treatment.

Cholinesterase inhibitors may improve hallucinations and cognitive symptoms in some patients.

Extreme caution is required with antipsychotic drugs because patients with dementia with Lewy bodies can develop profound neuroleptic sensitivity, including worsening parkinsonism, altered consciousness, or potentially life-threatening reactions.

Management should therefore be coordinated with neurology, geriatrics, or psychiatry.

Referral

Referral depends on the suspected cause.

An ophthalmologist should evaluate patients with significant visual loss or suspected ocular disease.

A neurologist should evaluate suspected seizures, migraine with unusual features, structural neurologic disease, Parkinsonism, or focal neurologic findings.

A psychiatrist may be appropriate when primary psychiatric disease is suspected or hallucinations are severely distressing and require psychotropic treatment.

Inpatient Considerations

Hospitalization may be required when hallucinations occur in the setting of delirium, severe metabolic disturbance, intoxication or withdrawal, severe agitation, or dangerous behavior.

Treatment should focus on correcting the underlying metabolic or toxic abnormality and ensuring patient safety.

Patients with severe agitation require careful monitoring to prevent injury to themselves or others.

Follow-Up

Follow-up should be tailored to the underlying condition.

Medication lists should be reviewed regularly because medications can trigger or worsen hallucinations.

Patients with Charles Bonnet syndrome benefit from periodic ophthalmic follow-up to optimize remaining visual function.

Patients with neurologic or psychiatric causes require appropriate specialist follow-up.

Patient Education

Reassurance is particularly important in patients with Charles Bonnet syndrome.

Patients should be informed that visual hallucinations associated with visual impairment are a recognized neurologic response to reduced visual input.

They should also be encouraged to report hallucinations openly rather than concealing them.

New hallucinations associated with confusion, weakness, severe headache, seizure activity, fever, or sudden neurologic changes require urgent medical evaluation.

Prognosis

The prognosis depends on the underlying cause.

Hallucinations caused by a reversible metabolic or toxic abnormality may resolve when the abnormality is corrected.

Charles Bonnet hallucinations may decrease with reassurance or improved visual function, but they can persist for months or years in some patients.

Hallucinations associated with chronic neurodegenerative disorders may recur or progress over time.

Complications

Visual hallucinations themselves may cause fear, anxiety, sleep disruption, social withdrawal, or unsafe behavior.

Patients may conceal symptoms because of fear of psychiatric stigma.

In delirium or dementia, hallucinations can contribute to agitation, falls, or self-injury.

The most important clinical task is therefore to distinguish relatively benign phenomena such as Charles Bonnet syndrome from hallucinations caused by potentially serious neurologic, metabolic, toxic, or psychiatric disease.

Ophthalmology – Gyrate Atrophy

Basics

Description

Gyrate atrophy of the choroid and retina is a rare, progressive autosomal recessive chorioretinal dystrophy caused by deficiency of the enzyme ornithine aminotransferase (OAT).

The disease typically begins during the first decade of life with:

• Nyctalopia
• Progressive loss of peripheral vision
• High myopia
• Progressive visual-field constriction

Characteristic sharply demarcated areas of peripheral chorioretinal atrophy gradually enlarge and coalesce. With advancing disease, the atrophy progresses toward the posterior pole, eventually resulting in loss of central vision.

Epidemiology

Gyrate atrophy is rare worldwide.

The highest reported prevalence is in Finland, where its frequency has been estimated at approximately 1 in 50,000.

Clinical manifestations usually begin during the first decade of life.

Risk Factors

The principal risk factor is inheritance of pathogenic mutations affecting ornithine aminotransferase.

Although the disorder occurs worldwide, a particularly large number of affected patients have historically been reported in Finland.

Genetics

Gyrate atrophy has an autosomal recessive inheritance pattern.

The responsible OAT gene is located on chromosome 10q26.

Numerous pathogenic variants have been identified.

Genetic counseling is appropriate for affected patients and their families.

Pathophysiology

The fundamental abnormality is deficiency of ornithine aminotransferase (OAT), a mitochondrial enzyme involved in ornithine metabolism.

OAT deficiency produces a dramatic elevation in circulating ornithine.

Plasma ornithine concentrations are typically approximately 10–20 times normal.

The markedly elevated ornithine concentration is believed to exert a toxic effect on the retinal pigment epithelium (RPE) and associated chorioretinal structures.

Progressive degeneration consequently involves:

• Retinal pigment epithelium
• Choriocapillaris
• Photoreceptors
• Other retinal structures as disease advances

The result is progressive chorioretinal atrophy and deterioration of retinal function.

Etiology

The disease results from OAT enzyme deficiency caused by pathogenic variants in the OAT gene.

The resulting hyperornithinemia is central to the development of retinal degeneration.

Commonly Associated Conditions

Although the ophthalmic manifestations dominate the clinical picture, systemic abnormalities have occasionally been reported.

These include:

• EEG abnormalities
• Hair abnormalities
• Skeletal muscle abnormalities demonstrated by CT or MRI
• Cerebral white-matter abnormalities
• Cerebral atrophy on MRI

Diagnosis

History

First Decade

Patients usually initially develop:

• Night blindness
• Decreased peripheral vision
• Myopia
• Astigmatism

Nyctalopia is frequently among the earliest manifestations.

Second Decade

During adolescence, patients commonly develop posterior subcapsular cataracts.

Later Disease

Progressive retinal degeneration causes increasingly severe constriction of the visual field.

Central visual acuity is initially relatively preserved but gradually deteriorates as the chorioretinal atrophy advances toward the posterior pole.

Significant central visual loss commonly develops by middle age.

Physical Examination

Refractive Error

Virtually all affected patients are myopic.

The degree of myopia may be substantial, historically reported in the approximate range of:

−4.00 to −20.00 D

Astigmatism is also common.

Lens Findings

Posterior subcapsular cataracts commonly become apparent by adolescence or early adulthood.

They may contribute substantially to visual deterioration but do not account for the progressive peripheral visual-field loss.

Fundus Findings

The funduscopic appearance is highly characteristic.

Early disease demonstrates multiple, sharply demarcated, round areas of chorioretinal atrophy involving the peripheral and midperipheral retina.

The abnormalities are typically:

• Bilateral
• Relatively symmetric
• Well circumscribed
• Initially separated by areas of relatively preserved retina

With time, individual areas of atrophy enlarge and coalesce.

The boundary between normal and atrophic retina characteristically develops a scalloped or gyrate appearance, giving the disease its name.

As the disorder progresses, chorioretinal atrophy extends centripetally toward the posterior pole.

In advanced disease, most or essentially all of the fundus may become involved.

Diagnostic Tests and Interpretation

Plasma Ornithine

Measurement of plasma ornithine concentration is a key diagnostic investigation.

Levels are generally approximately 10–20 times above normal.

Marked hyperornithinemia in a patient with the characteristic fundus appearance strongly supports the diagnosis.

Molecular genetic testing of the OAT gene can provide definitive genetic confirmation.

Fluorescein Angiography

Fluorescein angiography typically demonstrates hyperfluorescence corresponding to areas of chorioretinal atrophy.

There may also be leakage near the transition between preserved and atrophic retinal tissue.

Optical Coherence Tomography

OCT is useful for evaluating the macula and documenting structural complications.

Potential findings include:

• Progressive retinal thinning and atrophy
• Cystoid macular edema
• Epiretinal membrane
• Outer retinal and RPE abnormalities

Electroretinography

ERG abnormalities develop early.

Initially, both:

• Scotopic responses
• Photopic responses

are reduced.

This indicates dysfunction involving both rod and cone systems.

As retinal degeneration progresses, ERG amplitudes continue to decline.

In advanced adulthood, ERG responses may become nondetectable.

Differential Diagnosis

The major differential diagnosis is choroideremia.

Choroideremia

Choroideremia also produces progressive degeneration of the choroid, RPE, and retina with nyctalopia and peripheral visual-field loss.

However, it is typically X-linked, primarily affecting males, whereas gyrate atrophy is autosomal recessive.

The characteristic scalloped lesions and markedly elevated plasma ornithine strongly support gyrate atrophy.

Other inherited retinal/choroidal dystrophies may also enter the differential diagnosis depending on the phenotype.

Treatment

There is currently no treatment that reliably reverses established chorioretinal atrophy.

The primary therapeutic strategy is to reduce plasma ornithine concentrations in an attempt to slow retinal degeneration.

Dietary Treatment

Low-Arginine Diet

A low-protein, arginine-restricted diet is the principal long-term treatment.

Arginine restriction reduces the amount of substrate available for production of ornithine and consequently lowers plasma ornithine concentrations.

Long-term dietary treatment may slow progression of chorioretinal degeneration, particularly when initiated early.

Evidence from affected siblings suggests that patients beginning dietary restriction at a younger age may experience slower progression than siblings beginning treatment later.

However, retinal degeneration may continue despite excellent dietary compliance.

Because substantial protein restriction can have nutritional consequences, dietary therapy should be supervised by clinicians and dietitians experienced in metabolic disease.

Pyridoxine Therapy

Some patients demonstrate biochemical responsiveness to vitamin B6 (pyridoxine).

Pyridoxine acts as a cofactor for ornithine aminotransferase and may increase residual enzyme activity in responsive mutations.

However, most patients are not pyridoxine responsive.

A therapeutic trial may therefore be considered with monitoring of plasma ornithine levels to determine whether a meaningful biochemical response occurs.

Cataract Treatment

Visually significant posterior subcapsular cataracts may be treated with cataract extraction.

Patients should be counseled that cataract removal addresses only the lenticular component of their visual impairment.

Postoperative visual potential may remain substantially limited by the underlying retinal and choroidal degeneration.

Ongoing Care

Follow-Up Recommendations

Gyrate atrophy is a lifelong progressive disease.

Regular ophthalmic follow-up should assess:

• Visual acuity
• Refraction
• Visual fields
• Cataract progression
• Macular status
• Extent of chorioretinal atrophy
• Development of cystoid macular edema or epiretinal membrane

Serial retinal imaging and functional testing can help document progression.

Patient Monitoring

Plasma ornithine levels should be monitored when dietary or pyridoxine therapy is being used.

Patients undergoing significant dietary protein and arginine restriction require appropriate nutritional supervision to ensure adequate growth and general health, particularly during childhood.

Patient Education

Patients and families should understand that gyrate atrophy is a hereditary and progressive retinal disease.

Early recognition is important because dietary reduction of ornithine may slow progression, particularly when treatment begins during childhood.

Genetic counseling should be offered to affected individuals and their families.

Low-vision rehabilitation should be considered as visual impairment progresses.

Prognosis

The long-term visual prognosis is generally poor.

The typical progression is:

Nyctalopia in childhood → peripheral chorioretinal atrophy → progressive visual-field constriction → posterior pole involvement → central visual loss

Despite treatment, retinal function usually continues to decline, although early and sustained reduction of plasma ornithine may slow the rate of progression.

Key Ophthalmology Points

Gyrate atrophy = OAT deficiency + hyperornithinemia + progressive scalloped chorioretinal atrophy.

The classic diagnostic combination is childhood nyctalopia, high myopia, sharply demarcated scalloped areas of peripheral chorioretinal atrophy, and plasma ornithine levels approximately 10–20 times normal.

Treatment centers on early arginine restriction, with a trial of pyridoxine in potentially responsive patients.

Ophthalmology – Guillain–Barré Syndrome and Fisher Syndrome Variant

Basics

Description

Guillain–Barré syndrome (GBS) is an acute immune-mediated inflammatory disorder predominantly affecting the peripheral nerves and nerve roots. The classic demyelinating form is also called acute inflammatory demyelinating polyneuropathy (AIDP).

The clinical spectrum includes:

• Classic Guillain–Barré syndrome
• Fisher syndrome (FS), also called Miller Fisher syndrome
• Bickerstaff brainstem encephalitis (BBE)
• Other less common GBS variants

The disorder is frequently postinfectious, resulting from an autoimmune response triggered by a preceding infection.

⚠️ Clinical Alert: Ascending paralysis can progress rapidly and involve the respiratory muscles, resulting in respiratory failure. Respiratory and autonomic monitoring is essential.

Epidemiology

The incidence of GBS is approximately 0.6–4 cases per 100,000 population.

Fisher syndrome represents approximately 1–7% of GBS-spectrum cases in Western countries, but may account for up to 25% in Japan.

Men are affected more frequently than women.

GBS can occur at any age but is most frequent from the third through seventh decades. Fisher syndrome has been reported to show peaks in approximately the fourth and sixth decades.

Risk Factors

Important precipitating factors include preceding infection, surgery, and occasionally immunization.

Antecedent Infections

Approximately two-thirds of patients report an infection before neurologic symptoms begin.

Important organisms include:

• Campylobacter jejuni
• Haemophilus influenzae
• Cytomegalovirus
• Epstein–Barr virus
• Other viral respiratory or gastrointestinal infections

Pathophysiology

GBS is primarily an immune-mediated attack on peripheral nerves.

An infectious or other antigenic exposure triggers antibodies and cellular immune responses that cross-react with components of peripheral nerves through molecular mimicry.

This can produce:

• Peripheral nerve demyelination
• Perivascular inflammatory infiltration
• Conduction block
• Variable secondary axonal injury
• Wallerian degeneration in severe disease

Certain GBS variants are more strongly associated with antibodies directed against specific neuronal gangliosides.

Anti-GQ1b Antibodies

Anti-GQ1b antibodies are particularly important in Fisher syndrome.

They are present in the great majority of patients with typical Fisher syndrome and correlate strongly with ophthalmoplegia and ataxia.

Etiology

The underlying mechanism is an autoimmune response following exposure to an antigen, usually from an antecedent infection.

The resulting immune response mistakenly targets peripheral nerve components.

Diagnosis

History

Classic GBS usually begins with acute or subacute weakness.

Weakness typically starts in the distal lower extremities and progresses proximally over hours to days, producing the characteristic ascending paralysis.

Sensory symptoms such as numbness, paresthesias, or neuropathic discomfort may occur but are usually less prominent than motor weakness.

As the disease progresses, cranial nerves may become involved, producing:

• Facial weakness
• Ptosis
• Diplopia
• Dysphagia
• Dysarthria

Bulbar and respiratory involvement can become life-threatening.

Fisher Syndrome Presentation

Fisher syndrome commonly presents differently from classic ascending GBS.

The characteristic initial complaints are:

• Diplopia
• Gait instability or ataxia

Physical Examination

Classic GBS

The characteristic neurologic findings include:

• Symmetric, usually ascending weakness
• Reduced or absent deep tendon reflexes
• Cranial nerve involvement
• Facial weakness
• Bulbar weakness
• Possible respiratory muscle weakness

Severe bulbar or respiratory weakness can result in apnea and respiratory failure.

Fisher Syndrome – Classic Triad

The classic Fisher syndrome triad consists of:

1. Ophthalmoplegia

Ptosis and ophthalmoparesis are prominent and may progress to essentially complete bilateral ophthalmoplegia.

2. Ataxia

Patients develop significant gait and limb ataxia.

3. Areflexia

Deep tendon reflexes are reduced or absent.

Ophthalmoplegia + Ataxia + Areflexia = Fisher syndrome

Ophthalmic Manifestations

Ptosis and ophthalmoparesis may occur throughout the GBS spectrum but are particularly characteristic of Fisher syndrome.

The ophthalmoplegia can be complex and may demonstrate both peripheral and central patterns.

Findings can include:

• Third cranial nerve paresis
• Fourth cranial nerve paresis
• Sixth cranial nerve paresis
• Symmetric ophthalmoplegia that does not correspond to an individual cranial nerve
• Internuclear ophthalmoplegia
• Vertical gaze abnormalities
• Nystagmus
• Supranuclear gaze abnormalities
• Ptosis

GBS, particularly Fisher syndrome, is an important cause of complete bilateral ophthalmoplegia.

Pupillary Abnormalities

Pupillary involvement can occur.

Some patients develop mydriasis with a poorly reactive pupil.

Light-near dissociation may also occur, in which the pupillary response to light is impaired while constriction during near effort is relatively preserved.

Bickerstaff Brainstem Encephalitis

Bickerstaff brainstem encephalitis overlaps clinically and immunologically with Fisher syndrome.

Characteristic features include:

• Ophthalmoplegia
• Ataxia
• Impaired consciousness
• Hyperreflexia

The presence of altered consciousness and pyramidal tract features helps distinguish BBE from typical Fisher syndrome.

Diagnostic Tests and Interpretation

Lumbar Puncture

The classic cerebrospinal fluid finding is albuminocytologic dissociation:

Elevated CSF protein with few or no white blood cells.

Importantly, CSF protein may remain normal during the first several days of illness. Therefore, a normal early lumbar puncture does not exclude GBS.

Electrodiagnostic Studies

Nerve conduction studies and electromyography may demonstrate a peripheral neuropathy with demyelinating features.

Findings may include:

• Slowed conduction velocity
• Prolonged distal motor latency
• Conduction block
• Prolonged or absent F waves

Some GBS variants predominantly produce axonal abnormalities rather than demyelination.

Anti-GQ1b Antibody

Serum anti-GQ1b IgG antibody is strongly associated with Fisher syndrome and is detected in more than 85% of typical cases.

It is particularly associated with:

• Ophthalmoplegia
• Ataxia

Anti-GQ1b antibodies can also occur in related GBS-spectrum disorders, including Bickerstaff brainstem encephalitis.

Imaging

GBS and Fisher syndrome are primarily clinical diagnoses supported by CSF and electrophysiologic findings.

MRI is principally useful for excluding alternative diagnoses.

Important alternatives include:

• Brainstem infarction
• Brainstem hemorrhage
• Brainstem encephalitis
• Demyelinating disease
• Structural brainstem lesions
• Wernicke encephalopathy

Brain MRI is frequently normal in GBS and Fisher syndrome.

Occasionally, MRI may demonstrate enhancement of cranial nerves or nerve roots.

Pathological Findings

Typical pathology demonstrates:

• Perivenular inflammatory infiltrates
• Segmental demyelination of peripheral nerves
• Variable axonal degeneration

Differential Diagnosis

Important differential diagnoses include:

• Myasthenia gravis
• Brainstem infarction
• Brainstem hemorrhage
• Brainstem encephalitis
• Brainstem tumor or other mass lesion
• Multiple sclerosis or another demyelinating disorder
• Wernicke encephalopathy
• Botulism
• Cavernous sinus disease

In a patient presenting with acute bilateral ophthalmoplegia, ataxia, and areflexia, Fisher syndrome should be strongly considered.

Treatment

Guillain–Barré Syndrome

Two established disease-modifying treatments are used for significant GBS:

Intravenous Immunoglobulin (IVIG)

IVIG is a standard first-line therapy.

Plasma Exchange

Plasmapheresis/plasma exchange is also an effective first-line treatment.

Both treatments can accelerate recovery in appropriately selected patients.

Routine corticosteroid monotherapy is not an effective treatment for classic GBS.

Fisher Syndrome

Fisher syndrome generally has an excellent spontaneous recovery rate.

Because the disease is uncommon and frequently self-limited, evidence supporting specific immunotherapy is less robust than for classic GBS.

Patients with severe disease, respiratory or bulbar involvement, substantial overlap with classic GBS, or Bickerstaff-spectrum disease require particularly close neurologic assessment.

General Management

GBS management extends well beyond immunotherapy.

Important supportive measures include:

• Respiratory monitoring
• Cardiac monitoring
• Monitoring for autonomic instability
• Thrombosis prevention when appropriate
• Physical and occupational rehabilitation
• Nutritional and swallowing support when required
• Prevention of pressure injuries and other complications of immobility

Management of Diplopia

Acute diplopia can be managed symptomatically with:

• Monocular occlusion
• Temporary prisms when appropriate

Persistent ocular misalignment should generally be observed initially because substantial spontaneous recovery may occur.

Corneal Protection

Facial weakness and incomplete eyelid closure can cause exposure keratopathy.

Patients may require:

• Frequent ocular lubrication
• Lubricating ointment
• Eyelid taping or other protective measures when necessary

The cornea should be monitored closely when facial paresis is severe.

Surgery

Surgery is rarely required during the acute disease.

If recovery eventually plateaus with persistent disabling strabismus, ophthalmoplegia, or ptosis, appropriately selected patients may undergo:

• Strabismus surgery
• Eyelid surgery

Surgery should generally be deferred until the neurologic and ocular alignment abnormalities have become stable.

Inpatient Considerations

Admission

Most patients with classic GBS require hospitalization.

Relatively mild and stable Fisher syndrome may occasionally be managed without admission, but careful neurologic assessment is required because overlap with more generalized GBS can occur.

⚠️ Emergency concern: Progressive weakness, bulbar dysfunction, declining respiratory function, severe autonomic instability, or cardiac arrhythmia requires intensive monitoring and potentially ICU management.

Respiratory Monitoring

Respiratory status should be assessed repeatedly because deterioration may occur rapidly.

Progressive respiratory failure requires early airway management and mechanical ventilation rather than waiting for overt respiratory collapse.

Autonomic Dysfunction

GBS can produce substantial autonomic instability, including:

• Bradycardia
• Tachycardia
• Cardiac arrhythmias
• Blood pressure fluctuations
• Other dysautonomic manifestations

Continuous cardiac monitoring may therefore be necessary in significant disease.

Rehabilitation

Physical and occupational therapy are important components of recovery.

Rehabilitation helps maintain joint mobility, prevent complications of immobility, and maximize recovery of strength and function.

Follow-Up

Patients should receive continued neurologic follow-up until recovery is complete or their neurologic deficits have clearly plateaued.

Patients with ophthalmoplegia require ophthalmologic or neuro-ophthalmologic follow-up when diplopia, ptosis, pupillary abnormalities, or exposure keratopathy persists.

Prognosis

Fisher Syndrome

The prognosis is generally excellent.

Recovery often begins within approximately 2 weeks, and substantial recovery commonly occurs within 3 months, although the exact course varies.

Guillain–Barré Syndrome

Most patients experience substantial neurologic recovery, although recovery may require weeks to months.

A subset is left with persistent weakness, sensory symptoms, fatigue, or other neurologic deficits.

Some patients experience recurrent episodes or evolve into a chronic immune-mediated neuropathy such as chronic inflammatory demyelinating polyneuropathy (CIDP).

Key Ophthalmology Points

The most important ophthalmic association is Fisher syndrome, characterized by the triad of ophthalmoplegia, ataxia, and areflexia.

Acute bilateral or complete ophthalmoplegia—particularly when accompanied by gait ataxia and absent reflexes—should prompt consideration of Fisher syndrome and testing for anti-GQ1b antibodies.

Despite the dramatic ophthalmoplegia, the ocular motor prognosis in Fisher syndrome is generally very good.

Ophthalmology – Granulomatous Uveitis

Basics

Description

Granulomatous uveitis is a nonspecific term describing intraocular inflammation with granulomatous features. It may present with a painful red eye, photophobia, floaters, and decreased vision, although the symptoms vary depending on the site and severity of inflammation.

A classic finding is the presence of large, greasy keratic precipitates, often described as mutton-fat keratic precipitates, on the corneal endothelium.

The inflammation may involve predominantly the anterior segment as anterior uveitis or iritis, the vitreous as intermediate uveitis, the retina and choroid as posterior uveitis, or the entire uveal tract as panuveitis.

Granulomatous uveitis is more often associated with an underlying systemic disease, infectious process, or specific ocular syndrome than nongranulomatous uveitis. It may be unilateral or bilateral, acute or chronic, and can occur at any age.

Risk Factors

Risk factors depend on the underlying cause.

Geographic exposure is important, particularly residence in or travel to areas endemic for infections such as tuberculosis, Lyme disease, or coccidioidomycosis.

Animal exposure may also be relevant. For example, certain exposure histories may increase suspicion for toxoplasmosis.

Ethnicity can provide a clue to systemic associations. Sarcoidosis, for example, has varying prevalence among different populations.

A history of penetrating ocular trauma or surgery involving the fellow eye may suggest sympathetic ophthalmia.

Disruption of the lens capsule following trauma or surgery may predispose to lens-associated uveitis.

Genetics

Granulomatous uveitis itself does not have a single genetic pattern.

Some associated diseases have genetic markers. For example, Vogt–Koyanagi–Harada disease has been associated with certain HLA-DR alleles.

Pathophysiology

The exact mechanism varies with the underlying condition.

Granulomatous inflammation may result from an autoimmune response, persistent immune activation against ocular antigens, or the host response to an infectious organism.

The inflammatory reaction typically involves macrophages, epithelioid cells, lymphocytes, and multinucleated giant cells.

Etiology

A substantial proportion of cases remain idiopathic despite appropriate evaluation.

Possible infectious causes include syphilis, tuberculosis, herpes simplex virus, varicella-zoster virus, cytomegalovirus, toxoplasmosis, Lyme disease, leprosy, coccidioidomycosis, and brucellosis.

Important noninfectious causes include sarcoidosis, Vogt–Koyanagi–Harada disease, sympathetic ophthalmia, granulomatosis with polyangiitis, and lens-associated uveitis.

Because treatment differs considerably between infectious and noninfectious causes, identifying the underlying etiology is essential whenever possible.

Commonly Associated Conditions

Granulomatous uveitis may be associated with sarcoidosis, syphilis, HSV, VZV, CMV, tuberculosis, toxoplasmosis, Lyme disease, leprosy, Vogt–Koyanagi–Harada disease, sympathetic ophthalmia, granulomatosis with polyangiitis, coccidioidomycosis, brucellosis, and lens-associated inflammation.

Diagnosis

History

A detailed medical and ocular history should be obtained.

The clinician should ask about prior ocular surgery, trauma, infections, systemic inflammatory disease, and medications.

A complete review of systems should include questions about joint pain, skin rashes, shortness of breath, swollen lymph nodes, headaches, hearing changes, hair loss, skin depigmentation, neurologic symptoms, ocular trauma, insect bites, sexually transmitted infections, tuberculosis exposure, animal exposure, and recent travel.

These findings can help direct the diagnostic workup.

Physical Examination

Visual Acuity

Vision may remain normal in mild disease or may be reduced when inflammation is severe or involves the macula, optic nerve, lens, vitreous, retina, or choroid.

Intraocular Pressure

Intraocular pressure is often reduced during active anterior inflammation because ciliary body dysfunction decreases aqueous production.

However, elevated intraocular pressure may occur in viral uveitis, chronic inflammatory disease, secondary angle damage, or as a response to corticosteroid therapy.

External Findings

External examination may occasionally provide clues to systemic disease.

For example, lacrimal gland enlargement, parotid enlargement, or facial nerve palsy may suggest sarcoidosis.

Conjunctival injection may be present, often with a ciliary flush around the limbus.

In Vogt–Koyanagi–Harada disease, perilimbal depigmentation known as Sugiura sign may develop.

Corneal Findings

Keratic precipitates are deposits of inflammatory cells on the posterior corneal surface.

In granulomatous disease, they are typically large, greasy, and mutton-fat in appearance and are often concentrated inferiorly.

Anterior Chamber Findings

Anterior chamber cells and flare are common.

Cells represent inflammatory cells floating in the aqueous humor.

Using the SUN grading system, anterior chamber cells are graded as follows: 0 for fewer than 1 cell, 0.5+ for 1–5 cells, 1+ for 6–15 cells, 2+ for 16–25 cells, 3+ for 26–50 cells, and 4+ for more than 50 cells in a standardized slit-lamp field.

Flare represents increased protein in the aqueous due to breakdown of the blood-aqueous barrier.

Flare is graded as 0 for none, 1+ for faint, 2+ for moderate with clear iris and lens details, 3+ for marked with hazy iris and lens details, and 4+ for intense flare with fibrin or a markedly turbid aqueous.

Iris Findings

Granulomatous uveitis may produce posterior synechiae, where the iris adheres to the anterior lens capsule.

Peripheral anterior synechiae may also occur.

Inflammatory iris nodules may develop at the pupillary margin, on the iris surface, or within the anterior chamber angle.

Lens Findings

Inflammatory deposits may be visible on the anterior lens capsule.

Patients with recurrent or chronic inflammation may develop posterior subcapsular cataracts, either from the inflammation itself or from prolonged corticosteroid therapy.

Vitreous Findings

Inflammatory cells in the vitreous indicate posterior involvement.

Aggregates of inflammatory cells may form snowballs, particularly in intermediate uveitis.

Posterior Segment Findings

Posterior inflammation may produce optic disc edema, retinal vascular sheathing, retinal vasculitis, focal retinal lesions, choroidal lesions, cystoid macular edema, choroidal granulomas, or exudative retinal detachment.

Diagnostic Tests and Interpretation

Laboratory Evaluation

Laboratory investigation should be directed by the history, review of systems, examination findings, and epidemiologic exposure.

Granulomatous uveitis generally warrants an etiologic evaluation even at the first presentation because of its stronger association with systemic and infectious disease.

A basic evaluation may include a complete blood count and syphilis testing.

Syphilis testing is particularly important because syphilitic uveitis can mimic almost any form of ocular inflammation.

Tuberculosis Testing

When tuberculosis is suspected, testing may include a tuberculin skin test or interferon-gamma release assay, together with appropriate chest imaging.

Sarcoidosis Testing

When sarcoidosis is suspected, chest imaging is important.

Serum ACE and lysozyme may provide supportive evidence but are not sufficiently specific to establish the diagnosis by themselves.

Lyme Disease

Lyme serology should be considered when there is an appropriate exposure history and compatible clinical findings.

Toxoplasmosis

Toxoplasma IgG and IgM testing may be supportive in selected cases, although ocular toxoplasmosis is often diagnosed primarily from the retinal appearance.

Granulomatosis With Polyangiitis

ANCA testing may be useful when granulomatosis with polyangiitis is suspected.

PCR Testing

Aqueous or vitreous PCR can be helpful when an infectious etiology is suspected.

PCR may be performed for HSV-1, HSV-2, VZV, CMV, and Toxoplasma, depending on the clinical pattern.

Imaging

B-Scan Ultrasonography

If media opacity prevents visualization of the posterior segment, B-scan ultrasound may identify vitritis, exudative retinal detachment, subretinal lesions, choroidal thickening, or optic nerve abnormalities.

Fluorescein Angiography

Fluorescein angiography can demonstrate retinal vasculitis, vascular leakage, papillitis, macular edema, and inflammatory retinal abnormalities.

Indocyanine Green Angiography

Indocyanine green angiography provides improved visualization of choroidal inflammatory abnormalities and may be especially useful in diseases such as VKH.

Chest Imaging

Chest radiography may identify hilar or mediastinal adenopathy associated with sarcoidosis or tuberculosis.

If chest radiography is nondiagnostic but suspicion for sarcoidosis remains high, chest CT may be considered.

Biopsy

Biopsy of an accessible conjunctival nodule, lacrimal gland lesion, lymph node, skin lesion, or other involved tissue can help establish diagnoses such as sarcoidosis.

Histopathology classically demonstrates epithelioid histiocytes and multinucleated giant cells within granulomas.

Differential Diagnosis

Important differential diagnoses include endophthalmitis, intraocular lymphoma, chronic retinal detachment, and lens-induced inflammatory disease.

Masquerade syndromes should be considered when the inflammation behaves atypically or does not respond as expected to therapy.

Treatment

Treatment depends critically on whether the uveitis is infectious or noninfectious.

First-Line Treatment

For noninfectious anterior granulomatous uveitis, topical corticosteroids, such as prednisolone acetate, are usually the main initial therapy.

Treatment is often started relatively aggressively and then tapered slowly according to the clinical response.

Cycloplegic agents, such as cyclopentolate, homatropine, or atropine, may be used to relieve pain and photophobia and to prevent or break posterior synechiae.

Treatment of an Identified Cause

When an infectious cause is identified, treatment should specifically target the underlying pathogen.

For example, tuberculosis-associated uveitis requires appropriate antituberculous therapy, syphilitic uveitis requires systemic antibiotic treatment, and herpetic disease requires appropriate antiviral therapy.

Corticosteroids in infectious uveitis should generally be used only in combination with appropriate antimicrobial treatment.

Second-Line Treatment

If important infectious causes have been excluded and inflammation remains inadequately controlled with topical therapy, periocular or systemic corticosteroids may be necessary.

Long-term oral corticosteroid therapy requires monitoring for systemic complications such as hypertension, diabetes, osteoporosis, infection, mood changes, and gastrointestinal effects.

Calcium and vitamin D supplementation and other bone-protective measures may be appropriate when prolonged systemic treatment is anticipated.

Immunomodulatory Therapy

Patients with chronic, recurrent, steroid-dependent, or steroid-resistant noninfectious uveitis may require immunomodulatory or immunosuppressive therapy.

This may include antimetabolites, calcineurin inhibitors, biologic therapies, or other steroid-sparing agents.

Such treatment is usually coordinated with a uveitis specialist and often a rheumatologist.

Intravitreal Steroid Therapy

Intravitreal corticosteroids may be used in selected severe noninfectious cases, particularly when posterior inflammation or macular edema is prominent.

Potential complications include cataract formation and ocular hypertension or glaucoma.

Infectious etiologies should be excluded before intraocular corticosteroids are administered.

Management of Increased Intraocular Pressure

Secondary ocular hypertension or glaucoma should be treated with appropriate pressure-lowering medications.

Persistent elevation or progressive glaucomatous damage may require referral to a glaucoma specialist.

Referral

Patients receiving long-term systemic corticosteroids should be followed by a primary care physician or appropriate medical specialist for monitoring of blood pressure, blood glucose, bone health, and other systemic adverse effects.

Patients who require immunomodulatory therapy may need rheumatology involvement.

If an underlying systemic disease is identified, referral should be directed appropriately, such as pulmonology for sarcoidosis or infectious disease for tuberculosis.

Cystoid macular edema may require a vitreoretinal specialist.

Persistent, recurrent, or diagnostically uncertain inflammation should be referred to a uveitis specialist.

Surgery and Other Procedures

Chronic uveitis and corticosteroid treatment may lead to visually significant cataract requiring cataract extraction and intraocular lens implantation.

Glaucoma that cannot be controlled medically may require trabeculectomy, glaucoma drainage device implantation, or another pressure-lowering procedure.

Pars plana vitrectomy may be useful for persistent vitreous opacities, diagnostic sampling, or selected posterior segment complications.

Long-acting intraocular corticosteroid implants may be considered in selected patients with chronic noninfectious posterior uveitis, but they carry substantial risks of cataract and glaucoma.

Inpatient Considerations

Hospitalization is usually unnecessary when disease is confined to the eye.

Admission may occasionally be required for serious systemic infection or when intravenous therapy is needed, such as selected cases of neurosyphilis or severe viral retinitis.

Follow-Up

Patients should be followed closely while inflammation remains active.

The frequency of examination depends on the severity, location, underlying cause, and treatment being used.

Corticosteroids should be tapered slowly as inflammation resolves to minimize rebound disease.

After remission, patients require periodic ophthalmic evaluation because recurrence is common.

Patient Monitoring

Monitoring should include visual acuity, intraocular pressure, anterior chamber inflammation, vitreous activity, retinal and choroidal findings, and macular status.

Patients taking systemic corticosteroids or immunosuppressive medications also require appropriate systemic laboratory and clinical monitoring.

Patient Education

Patients should understand that granulomatous uveitis may be chronic or recurrent.

They should seek prompt evaluation for recurrence of redness, pain, photophobia, floaters, or decreased vision.

They should also understand the importance of following a prescribed corticosteroid taper rather than stopping treatment abruptly.

Untreated or inadequately treated inflammation can result in permanent visual loss.

Prognosis

The visual prognosis depends on the underlying etiology, severity and duration of inflammation, response to treatment, and development of complications.

Many patients maintain good visual function when the cause is identified and the inflammation is appropriately controlled.

The prognosis becomes less favorable when there is cataract, glaucoma, chronic cystoid macular edema, retinal or choroidal scarring, or recurrent severe inflammation.

Complications

Important complications include cataract, secondary glaucoma, cystoid macular edema, exudative retinal detachment, retinal pigment epithelial atrophy, posterior synechiae, band keratopathy, and permanent visual impairment.

Ophthalmology– Goldenhar Syndrome

Basics

Description

Goldenhar syndrome is a congenital craniofacial disorder within the oculo-auriculo-vertebral spectrum (OAVS). It is characterized by a variable combination of epibulbar choristomas, preauricular skin tags or appendages, vertebral abnormalities, and hemifacial microsomia.

The abnormalities usually involve structures derived from the first and second branchial arches. Ocular involvement is common and may affect the conjunctiva, cornea, eyelids, lacrimal system, ocular motility, and visual development.

Epidemiology

Goldenhar syndrome occurs in approximately 1 in 3,500 to 5,600 births. Males are affected somewhat more frequently than females.

The severity and combination of abnormalities vary widely among affected individuals.

Risk Factors

No definitive environmental or maternal risk factor has been established.

Most cases occur sporadically.

Genetics

Most individuals with Goldenhar syndrome have no affected family members.

Both autosomal dominant and autosomal recessive inheritance have occasionally been reported. Familial cases with bilateral auricular involvement may be more suggestive of inherited disease.

Several chromosomal abnormalities have been associated with the phenotype, including abnormalities involving 5p and 22q11.2.

A number of genetic loci have been proposed, and mutations involving SALL1 have been identified in some patients with overlapping phenotypes.

Because the genetic basis is heterogeneous, genetic evaluation is useful when there are atypical findings, multiple affected relatives, or associated systemic abnormalities.

Pathophysiology

Goldenhar syndrome is believed to result from abnormal embryologic development affecting the first and second pharyngeal arches.

One proposed mechanism is impaired migration or development of neural crest cells, which contribute to formation of the craniofacial skeleton, connective tissues, and other structures.

Disruption of these developmental pathways produces variable abnormalities of the maxilla, mandible, ears, vertebrae, eyelids, and ocular surface.

Etiology

The exact etiology is heterogeneous and incompletely understood.

Abnormal development of neural crest-derived structures and the first and second branchial arches is believed to be central to the disorder.

The ocular abnormalities are related particularly to abnormal development of tissues derived from the first branchial arch and adjacent craniofacial structures.

Commonly Associated Conditions

The characteristic craniofacial finding is hemifacial microsomia, in which one side of the face is underdeveloped.

Auricular abnormalities are common and may include microtia, malformed external ears, preauricular appendages, and hearing loss or deafness.

Vertebral abnormalities may cause scoliosis or torticollis.

Other patients have associated cardiovascular, neurologic, musculoskeletal, renal, or genitourinary abnormalities.

Nasal and airway abnormalities may also occur.

Diagnosis

History

A detailed family history should be obtained, with attention to craniofacial abnormalities, hearing loss, ear deformities, vertebral abnormalities, and similar ocular findings.

Developmental history and symptoms related to hearing, breathing, feeding, renal function, or neurologic problems should also be reviewed.

Ophthalmic Examination

A complete ophthalmic examination is essential because several abnormalities can interfere with visual development.

Epibulbar Dermoid

The most common ocular finding is an epibulbar or limbal dermoid.

It is classically located in the inferotemporal limbal region and is usually ipsilateral to the more severely affected side of the face.

The lesion is a congenital choristoma composed of normal tissue located in an abnormal position. It can contain hair follicles and occasionally protruding cilia.

A large limbal dermoid can distort the corneal curvature and cause significant astigmatism, which may lead to amblyopia.

Lipodermoid

A lipodermoid, or dermolipoma, is another common choristoma.

It is usually located temporally, often in the superotemporal or lateral conjunctival fornix. It may extend posteriorly toward orbital tissues and extraocular muscles.

Strabismus and Ocular Motility

Ocular alignment and motility should be carefully assessed.

Duane syndrome and other ocular motility disturbances have been associated with Goldenhar syndrome.

Strabismus itself may contribute to amblyopia.

Eyelid Abnormalities

An upper eyelid coloboma may occur and can sometimes be associated with adhesion between the eyelid and globe.

Other less common abnormalities include ptosis and shortening or distortion of the palpebral fissure.

If an eyelid coloboma prevents adequate ocular surface coverage, exposure-related corneal damage may occur.

Lacrimal Abnormalities

Congenital anomalies of the lacrimal drainage system may occur and can produce chronic tearing or recurrent infection.

Corneal Sensation and Tear Production

Some patients have decreased corneal sensation or reduced tear production.

When severe, these abnormalities can lead to neurotrophic or exposure-related corneal ulceration.

Microphthalmia and Posterior Segment Findings

Less commonly, patients may have microphthalmia, optic nerve hypoplasia, or macular hypoplasia.

The caruncle can also be absent, displaced, or otherwise abnormal.

Visual Assessment

Visual acuity should be assessed using age-appropriate techniques.

Particular attention should be paid to refractive error and amblyopia, because limbal dermoids can induce significant astigmatism even when the lesion itself does not obstruct the visual axis.

Cycloplegic refraction is therefore important in children.

Systemic Examination

A complete systemic evaluation should assess for facial asymmetry, mandibular and maxillary hypoplasia, preauricular appendages, microtia, vertebral abnormalities, hearing impairment, cardiac defects, and renal abnormalities.

Because the syndrome is multisystem, evaluation frequently requires several specialties.

Diagnostic Tests and Interpretation

Laboratory Testing

Routine laboratory testing is not required when the syndrome is isolated and the diagnosis is clinically evident.

Laboratory evaluation should be directed by associated systemic findings, particularly when renal or genitourinary abnormalities are suspected.

Imaging

Facial and neurologic imaging may be obtained when significant craniofacial abnormalities are present.

Cervical spine imaging is often useful because vertebral abnormalities are an important component of the syndrome.

CT or MRI may be indicated depending on associated craniofacial, neurologic, or orbital abnormalities.

Audiology

All affected patients should undergo appropriate hearing assessment, because hearing impairment is common and may substantially affect language development.

Renal Evaluation

A renal ultrasound may be appropriate when there are clinical findings suggesting renal involvement or as part of a broader syndromic evaluation.

Genetic Evaluation

Genetics consultation can assist with diagnosis, identification of associated syndromes, selection of molecular or chromosomal testing, and recurrence counseling.

Pathological Findings

Epibulbar dermoids contain collagenous connective tissue covered by conjunctival or corneal epithelium.

They may contain skin appendages such as hair follicles, sebaceous glands, or sweat glands, reflecting their choristomatous nature.

Differential Diagnosis

Conditions with overlapping craniofacial abnormalities include Treacher Collins syndrome, Pierre Robin sequence, Townes-Brocks syndrome, oculoectodermal syndrome, and other craniofacial or branchial arch disorders.

The characteristic combination of epibulbar dermoid, ear abnormalities, hemifacial microsomia, and vertebral defects strongly supports the diagnosis of Goldenhar syndrome.

Treatment

There is no medication that treats the underlying congenital disorder.

Management is directed toward preserving vision, correcting associated abnormalities, and treating systemic complications.

Amblyopia Treatment

Amblyopia should be treated promptly when present.

This may involve full correction of refractive error, patching, or other standard amblyopia therapy.

Because astigmatism induced by a limbal dermoid is a common cause of amblyopia, accurate optical correction is particularly important.

Surgical Treatment

Limbal Dermoid

Surgical excision of a limbal dermoid may be considered when there is significant cosmetic concern, chronic irritation, foreign-body sensation, induced astigmatism contributing to amblyopia, progressive corneal involvement, or other corneal complications.

Surgery does not always eliminate the induced astigmatism, so refractive and amblyopia treatment may still be required afterward.

Depending on the depth and size of the lesion, ocular surface reconstruction or corneal procedures may be necessary.

Lipodermoid

Lipodermoid excision should be approached cautiously.

These lesions may extend deeply and can lie close to extraocular muscles, the lacrimal gland, and orbital structures. Aggressive removal can cause restrictive strabismus, scarring, or other complications.

Therefore, only the symptomatic or cosmetically significant accessible portion may be removed in selected cases.

Eyelid Surgery

Eyelid colobomas, ptosis, and other lid abnormalities may require reconstructive surgery, particularly when the cornea is exposed or the visual axis is obstructed.

Craniofacial Surgery

Craniofacial and plastic surgical procedures may be required for significant hemifacial microsomia, mandibular hypoplasia, auricular abnormalities, or other facial malformations.

Treatment is often staged according to growth and functional needs.

Referral

Management is frequently multidisciplinary.

Patients may require referral to ophthalmology, pediatric ophthalmology, craniofacial or plastic surgery, otolaryngology, audiology, genetics, orthodontics, oral and maxillofacial surgery, and other specialties according to the associated abnormalities.

Ongoing Care and Follow-Up

Children require regular ophthalmologic follow-up to monitor visual acuity, refractive error, amblyopia, strabismus, corneal health, and growth or symptoms related to choristomas.

A limbal dermoid that remains stable and asymptomatic may be observed, but refractive effects should still be monitored carefully.

Hearing, craniofacial development, vertebral abnormalities, and associated systemic conditions should also be followed by the appropriate specialists.

Patient Education

Families should understand that Goldenhar syndrome has a wide spectrum of severity and that not every affected child develops all associated abnormalities.

The importance of early treatment of refractive error and amblyopia should be emphasized because visual loss from amblyopia may be preventable.

Children with hearing impairment should receive early audiologic intervention and appropriate educational support.

Genetic counseling may help families understand the usually sporadic nature of the disorder and the possibility of recurrence in familial cases.

Prognosis

The ocular prognosis is generally good when amblyopia, refractive error, exposure, and strabismus are recognized and treated early.

Visual outcome may be less favorable when significant microphthalmia, optic nerve hypoplasia, macular abnormalities, or severe corneal disease is present.

Overall prognosis depends largely on the severity of associated craniofacial and systemic abnormalities.

Complications

Ocular complications include amblyopia, significant astigmatism, strabismus, corneal dellen, exposure keratopathy, neurotrophic corneal disease, and corneal ulceration.

Large or symptomatic choristomas may cause chronic irritation or progressive corneal distortion.

Associated hearing impairment and craniofacial abnormalities can also substantially affect development and quality of life if they are not identified and managed early.

Ophthalmology – Giant Cell Arteritis

Basics

Description

Giant cell arteritis (GCA), also called temporal arteritis, is a systemic inflammatory vasculitis involving predominantly medium- and large-sized arteries. Inflammation within the arterial wall causes intimal proliferation, progressive narrowing of the vascular lumen, and ultimately tissue ischemia.

GCA is one of the most important ophthalmic emergencies because it can produce sudden, severe, and usually irreversible visual loss. Once one eye is affected, the fellow eye is at substantial risk if treatment is not started immediately. Systemic glucocorticoid therapy therefore should not be delayed while awaiting confirmatory testing when clinical suspicion is high. 

The most common ocular cause of visual loss is arteritic anterior ischemic optic neuropathy (AAION). Other ocular ischemic manifestations include central or branch retinal artery occlusion, cilioretinal artery occlusion, posterior ischemic optic neuropathy, and ocular ischemic syndrome.

Epidemiology

GCA occurs almost exclusively in adults older than 50 years and becomes increasingly common with advancing age. Women are affected more frequently than men, and the disease is particularly common in individuals of Northern European or Scandinavian ancestry. 

Genetic susceptibility appears to contribute to disease risk. Associations with particular HLA class II alleles, especially HLA-DRB1 variants, have been described, although GCA is not a simple Mendelian genetic disorder.

Prevention

There is no established method for preventing the development of GCA.

The major preventable complication is permanent visual loss, and prevention depends on recognizing the disease promptly and initiating adequate glucocorticoid therapy before irreversible ischemic injury occurs.

Pathophysiology

Both the innate and adaptive immune systems contribute to GCA.

Activation of dendritic cells within susceptible arterial walls promotes recruitment and activation of CD4-positive T lymphocytes and macrophages. These cells release inflammatory cytokines and organize into a granulomatous inflammatory response.

Macrophages and multinucleated giant cells may accumulate near the internal elastic lamina and contribute to destruction of the arterial wall.

Cytokines such as interleukin-6 contribute to the systemic acute-phase response, producing elevated inflammatory markers and constitutional symptoms.

Progressive inflammation produces intimal hyperplasia, luminal stenosis, thrombosis, and vascular occlusion, resulting in ischemia of structures supplied by the affected arteries.

Etiology

The precise cause of GCA remains unknown.

It is thought to develop in genetically susceptible older individuals after inappropriate activation of the immune system. Infectious triggers have been proposed, but no single infectious organism has been established as the cause.

Commonly Associated Conditions

GCA is strongly associated with polymyalgia rheumatica (PMR).

PMR typically causes bilateral aching and morning stiffness involving the shoulder girdle, neck, hips, and pelvic girdle. The two conditions can occur independently or together.

Diagnosis

History

Patients older than 50 years with possible GCA should be specifically questioned about systemic, cranial, and visual symptoms.

Constitutional manifestations may include fatigue, malaise, fever, decreased appetite, night sweats, and unintentional weight loss.

A new-onset or substantially changed headache is a common presenting symptom. The headache may be temporal but can occur elsewhere.

Patients may describe scalp tenderness, such as discomfort when brushing their hair or resting the head on a pillow.

Jaw claudication is particularly suggestive of GCA. Patients describe aching or fatigue of the jaw muscles when chewing that improves with rest. Tongue claudication and facial pain occur less frequently.

Symptoms of associated polymyalgia rheumatica include proximal muscle aching and marked morning stiffness.

Visual Symptoms

Visual manifestations require urgent attention.

Patients may experience transient monocular visual loss, episodes of dimming or graying of vision, diplopia, or sudden permanent visual loss.

Importantly, some patients with ocular GCA have few or no constitutional symptoms. Therefore, the absence of headache, jaw claudication, fever, or polymyalgia symptoms does not exclude the diagnosis.

Physical Examination

Temporal Arteries

The temporal arteries should be examined for tenderness, thickening, nodularity, reduced pulsation, or absence of pulse.

A normal temporal artery examination does not exclude GCA.

Arteritic Anterior Ischemic Optic Neuropathy

The classic ophthalmic manifestation is AAION.

The optic disc is typically markedly swollen and often has a characteristic pale or chalky-white appearance, in contrast to the more frequently hyperemic disc swelling seen in nonarteritic anterior ischemic optic neuropathy.

Visual acuity may be profoundly reduced. A relative afferent pupillary defect, dyschromatopsia, and severe visual-field loss are common when involvement is unilateral or asymmetric.

Later, the optic disc becomes pale and atrophic.

Retinal Arterial Occlusion

GCA can cause central, branch, or cilioretinal artery occlusion.

When an older patient develops retinal arterial occlusion without an obvious embolic source, especially in association with systemic symptoms or elevated inflammatory markers, GCA must be considered urgently.

Diplopia

Transient or persistent diplopia may result from ischemia affecting the third, fourth, or sixth cranial nerve or their vascular supply.

Diagnostic Tests and Interpretation

Inflammatory Markers

There is no single laboratory test that definitively confirms or excludes GCA.

The initial laboratory evaluation typically includes erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), complete blood count, and platelet count.

Most patients have elevated ESR and CRP, but normal inflammatory markers can occasionally occur. Consequently, a normal ESR alone must never be used to exclude GCA when the clinical presentation is strongly suggestive.

CRP is often particularly useful because it responds rapidly to systemic inflammation and is less strongly influenced by factors such as age and anemia.

Thrombocytosis and a normocytic anemia may provide additional supportive evidence.

Vascular Ultrasound

Modern practice increasingly uses vascular ultrasonography in the initial evaluation of suspected GCA when appropriate expertise is available.

The updated EULAR imaging recommendations identify ultrasound of the temporal and axillary arteries as the first-line imaging test in suspected GCA, with characteristic findings including arterial wall thickening and the hypoechoic “halo” sign. 

Ultrasound is operator dependent and should ideally be performed rapidly because glucocorticoid therapy can reduce inflammatory imaging findings.

Temporal Artery Biopsy

Temporal artery biopsy (TAB) remains an important method of confirming cranial GCA, particularly where vascular ultrasound expertise is limited or when imaging is inconclusive.

Biopsy should not delay treatment in a patient with threatened or established visual loss.

The ACR/Vasculitis Foundation guideline favors obtaining an adequate biopsy specimen and recommends biopsy relatively soon after glucocorticoid initiation when used diagnostically. 

Because GCA can produce skip lesions, a negative biopsy does not completely exclude the disease.

If the biopsy is negative but clinical suspicion remains high, additional vascular imaging or evaluation of the contralateral temporal artery may be appropriate.

Large-Vessel Imaging

GCA can involve the aorta and its major branches in addition to the cranial arteries.

Depending on the clinical presentation, CT angiography, MR angiography, PET imaging, or vascular ultrasound may be used to identify extracranial large-vessel involvement. Current guidelines recognize vascular imaging as an important component of diagnosis and assessment. 

Fluorescein Angiography

In patients with suspected ocular ischemia, fluorescein angiography may show delayed or patchy choroidal filling, prolonged retinal arterial filling, and areas of choroidal nonperfusion.

These findings can support the diagnosis of arteritic ischemic optic neuropathy but do not replace systemic evaluation for GCA.

Pathological Findings

Temporal artery biopsy classically demonstrates granulomatous inflammation involving the arterial wall, often with lymphocytes, macrophages, and multinucleated giant cells.

Giant cells are characteristic but not required for the diagnosis.

Disruption of the internal elastic lamina, intimal thickening, and luminal narrowing may be present.

Inflammation may occur in discontinuous segments, producing the characteristic skip lesions.

Differential Diagnosis

The major ophthalmic differential diagnosis is nonarteritic anterior ischemic optic neuropathy (NAION).

Compared with NAION, AAION generally occurs in an older patient, produces more profound visual loss, and is more likely to show markedly pale or chalky optic disc swelling.

Other conditions that may mimic portions of the clinical syndrome include other vasculitides, infectious diseases, compressive optic neuropathy, retinal vascular occlusion from embolic disease, and inflammatory optic neuropathies.

Treatment

GCA is a medical and ophthalmic emergency when visual symptoms are present.

The primary goal is to prevent additional ischemic injury, particularly blindness in the fellow eye, stroke, and other vascular complications.

Glucocorticoid Treatment

High-dose systemic glucocorticoids remain the foundation of initial therapy. Treatment should begin immediately when GCA is strongly suspected and should not wait for biopsy or imaging confirmation. 

For patients without visual ischemia, current guidelines recommend high-dose oral glucocorticoid therapy, with the precise regimen individualized to clinical circumstances. 

For patients with threatened or established visual loss or other cranial ischemic complications, pulse intravenous glucocorticoids such as methylprednisolone are commonly used initially, followed by high-dose oral glucocorticoid therapy. The ACR/Vasculitis Foundation guideline conditionally favors IV pulse glucocorticoids in patients with threatened vision loss. 

Tocilizumab and Steroid-Sparing Therapy

Modern treatment increasingly incorporates tocilizumab, an interleukin-6 receptor inhibitor, to reduce relapse and cumulative glucocorticoid exposure.

The ACR/Vasculitis Foundation guideline conditionally recommends tocilizumab plus glucocorticoids over glucocorticoids alone for many patients with newly diagnosed GCA. 

Methotrexate may be considered as an alternative steroid-sparing agent in selected patients, particularly when tocilizumab is unsuitable.

Treatment decisions should generally involve rheumatology or another physician experienced in systemic vasculitis.

Glucocorticoid Taper

Once disease control has been achieved, glucocorticoids are gradually tapered.

The taper must be individualized according to symptoms, inflammatory markers, recurrence risk, treatment-related toxicity, and use of steroid-sparing therapy.

EULAR guidance recommends reducing glucocorticoids progressively after remission rather than maintaining prolonged high doses; many patients still require treatment for an extended period. 

Rapid tapering can precipitate relapse.

Management of Glucocorticoid Complications

Because affected patients are usually older and may require prolonged treatment, complications of glucocorticoids are clinically important.

Patients require assessment and prevention of osteoporosis, hyperglycemia or diabetes, hypertension, infection, gastrointestinal complications, weight gain, mood disturbance, sleep disruption, cataract, and glaucoma.

Calcium and vitamin D supplementation, osteoporosis risk assessment, and additional bone-protective therapy may be appropriate depending on individual risk.

Referral

Patients with suspected ocular GCA require immediate ophthalmologic evaluation and urgent systemic treatment.

Rheumatology or internal medicine involvement is important for confirmation of the diagnosis, glucocorticoid tapering, steroid-sparing therapy, and monitoring of systemic vascular disease.

Patients with substantial visual impairment may benefit from low-vision rehabilitation.

Ongoing Care and Follow-Up

Follow-up should assess both disease activity and treatment toxicity.

Patients should be questioned repeatedly about recurrence of headache, scalp tenderness, jaw claudication, polymyalgia symptoms, constitutional symptoms, transient visual disturbances, or new visual loss.

ESR and CRP can be useful in monitoring many patients, but clinical assessment remains essential. This is particularly important in patients receiving tocilizumab because IL-6 blockade can suppress CRP and ESR even when clinical disease assessment remains necessary.

Large-vessel disease may require periodic vascular imaging depending on the initial pattern of arterial involvement and subsequent clinical course.

Patient Education

Patients should understand that recurrent symptoms can indicate disease relapse even while taking treatment.

They should seek immediate medical attention for any new transient or permanent visual disturbance, including dimming, graying, a curtain over the vision, or diplopia.

They should also report recurrent headache, scalp tenderness, jaw pain with chewing, or symptoms of polymyalgia rheumatica.

The adverse effects of long-term glucocorticoid therapy and the importance of medication adherence and laboratory monitoring should be carefully explained.

Prognosis

The prognosis for recovery of vision after established arteritic ischemic optic neuropathy is poor. Treatment is primarily intended to prevent further deterioration and protect the fellow eye rather than restore already infarcted optic nerve tissue.

Visual deterioration can occasionally continue during the first days after treatment is started, emphasizing the importance of rapid recognition and therapy.

Without treatment, the risk of sequential involvement of the fellow eye is very high. Prompt systemic glucocorticoids dramatically reduce this risk.

The systemic prognosis is generally favorable with appropriate treatment, although relapses are common and patients require long-term monitoring.

Complications

The principal ophthalmic complications are permanent severe visual loss from AAION, retinal arterial occlusion, posterior ischemic optic neuropathy, and bilateral blindness.

Systemic vascular complications include ischemic stroke, aortic aneurysm or dissection, myocardial ischemia, and less commonly mesenteric ischemia.

Treatment itself can cause substantial morbidity through long-term glucocorticoid exposure, making careful steroid tapering and the use of appropriate steroid-sparing therapies important components of modern management. 

Ophthalmology – Fuchs’ Heterochromic Iridocyclitis

Basics

Description

Fuchs’ heterochromic iridocyclitis (FHI), also called Fuchs uveitis syndrome, is a chronic, usually unilateral, low-grade anterior uveitis characterized by diffuse iris atrophy, heterochromia, fine stellate keratic precipitates, and minimal external inflammation.

The condition is often relatively asymptomatic. Patients may have only mild blurred vision or floaters, and the eye is typically white and quiet, without the marked pain, photophobia, and redness seen in many other forms of anterior uveitis.

Although traditionally considered unilateral, bilateral disease is recognized and may make heterochromia less obvious.

A strong association exists between FHI and rubella virus, and chronic intraocular immune responses to rubella antigens are thought to play an important etiologic role.

Two major long-term complications are cataract and secondary glaucoma.

Epidemiology

FHI accounts for a relatively small proportion of anterior uveitis cases. It has been estimated to represent less than approximately 6% of anterior uveitis seen in tertiary referral settings.

Its true prevalence may be underestimated because many patients have minimal symptoms and may remain undiagnosed until they develop cataract, glaucoma, or vitreous opacities.

The frequency of FHI has declined in populations with widespread rubella vaccination, particularly among individuals born after introduction of routine childhood immunization programs.

Risk Factors

A history of lack of rubella vaccination or residence in a region without an effective rubella vaccination program may increase risk.

Because the disease may be nearly asymptomatic, patients who do not receive routine eye examinations may not be diagnosed until complications such as advanced glaucoma or visually significant cataract have developed.

No consistent genetic predisposition has been established.

Prevention

The principal preventive strategy is universal rubella vaccination.

Vaccination reduces circulation of rubella virus and appears to reduce the incidence of Fuchs uveitis syndrome in immunized populations.

Pediatric Considerations

FHI is less common among children born after widespread adoption of rubella vaccination.

When the condition is diagnosed in a child or young adult, the patient’s and maternal rubella vaccination history may be relevant.

Pregnancy Considerations

In a pregnant patient with clinical findings compatible with FHI, assessment of rubella immunity is important because primary rubella infection during pregnancy, especially early gestation, can cause congenital rubella syndrome.

The presence of FHI itself does not mean that the patient has an acute systemic rubella infection.

Pathophysiology

Fuchs uveitis syndrome is thought to result from a chronic, localized intraocular immune response, frequently associated with persistent exposure to rubella viral antigens.

A predominantly CD8-positive T-cell-mediated immune response has been demonstrated within the eye.

This chronic low-grade inflammation results in progressive iris stromal atrophy, characteristic keratic precipitates, abnormalities of the anterior chamber angle vessels, and eventually complications such as cataract and glaucoma.

Unlike many other forms of anterior uveitis, the inflammatory response is usually mild and does not typically produce posterior synechiae.

Etiology

Evidence strongly supports an association with rubella virus.

Intraocular production of rubella-specific antibodies has been detected in a high proportion of patients with the classic clinical syndrome.

Rubella viral RNA has also been detected in some ocular samples, especially in younger patients.

The disease is therefore thought to represent a chronic ocular immune response related to prior rubella infection rather than active systemic rubella disease.

Commonly Associated Conditions

The two most important associated ocular complications are cataract and glaucoma.

Cataract develops in a substantial proportion of affected eyes, often becoming the major cause of reduced vision.

Secondary glaucoma occurs less frequently but may be difficult to control and can cause permanent optic nerve damage.

Vitreous opacities are also common and can produce symptomatic floaters or reduced visual quality.

Diagnosis

History

Patients are commonly young or middle-aged and may be asymptomatic.

When symptoms occur, they may include mild unilateral blurred vision, gradual change in iris color, floaters, or mild ocular discomfort.

Severe pain, marked photophobia, and prominent redness are unusual and should raise suspicion for another diagnosis.

Some patients first present because of progressive visual loss from cataract or glaucoma.

Physical Examination

External Appearance

The affected eye usually appears white and quiet, despite the presence of chronic intraocular inflammation.

This absence of prominent conjunctival injection is an important diagnostic clue.

Heterochromia

Iris heterochromia is common.

In patients with dark irides, the affected eye typically appears lighter because of progressive iris stromal atrophy.

In patients with light-colored irides, the affected eye may paradoxically appear darker because thinning of the anterior iris stroma allows greater visualization of the underlying pigment epithelium.

In bilateral disease, obvious heterochromia may be absent.

Keratic Precipitates

A characteristic finding is the presence of diffuse, fine, stellate, nongranulomatous keratic precipitates distributed widely over the corneal endothelium.

Unlike the inferiorly concentrated keratic precipitates seen in many other forms of anterior uveitis, those in FHI are often diffusely distributed.

Anterior Chamber

A mild chronic anterior chamber cellular reaction may be present.

Inflammation is usually low grade.

Posterior synechiae are typically absent, which is a useful distinguishing feature from many other chronic anterior uveitides.

Peripheral anterior synechiae are also not characteristic.

Iris Atrophy

Diffuse iris stromal atrophy is typical and contributes to heterochromia.

The iris architecture may become less distinct over time.

Anterior Chamber Angle

Gonioscopy may demonstrate abnormal fine vessels crossing or bridging the anterior chamber angle.

These fragile vessels are clinically important because they may bleed during surgery or other intraocular manipulation.

Cataract

Cataract is a very common long-term complication and may become the principal cause of visual impairment.

Glaucoma

Secondary glaucoma may develop and requires careful long-term monitoring because FHI is often asymptomatic.

Vitreous

Vitreous cells and opacities are common and may cause floaters or reduced visual quality.

Posterior segment disease is otherwise uncommon, although occasional chorioretinal scars or cystoid macular edema may occur.

Diagnostic Tests and Interpretation

Clinical Diagnosis

In many patients, the diagnosis can be made from the characteristic clinical pattern of:

quiet eye + diffuse stellate keratic precipitates + iris atrophy or heterochromia + absence of posterior synechiae + vitreous involvement.

Not every finding is present simultaneously, so repeated examinations may be helpful.

Intraocular Rubella Antibody Testing

When the diagnosis is uncertain, analysis of aqueous humor for intraocular rubella antibody production can provide strong laboratory support.

A modified Goldmann–Witmer coefficient or antibody index may be used to compare intraocular and serum rubella-specific antibody levels.

Detection of significant intraocular rubella antibody production strongly supports FHI, while absence of such antibody makes the diagnosis less likely in a clinically ambiguous case.

This testing is generally reserved for selected patients rather than routinely performed in every classic case.

Oligoclonal IgG

Intraocular oligoclonal IgG has been reported in FHI, but it is not specific enough to replace clinical diagnosis or pathogen-directed antibody testing.

Photography

External and slit-lamp photography may be useful to document heterochromia, iris atrophy, cataract progression, and other structural changes.

Pathological Findings

Histopathologic specimens demonstrate lymphocytes and plasma cells, supporting the concept of a chronic immune-mediated response.

These findings are consistent with persistent viral antigen-driven intraocular inflammation.

Differential Diagnosis

The differential diagnosis includes other causes of chronic unilateral anterior uveitis, especially herpes simplex virus, varicella-zoster virus, toxoplasmosis-associated uveitis, and Posner–Schlossman syndrome.

Herpetic anterior uveitis may produce elevated intraocular pressure and iris atrophy but is more likely to show sectoral rather than diffuse iris atrophy and may be associated with corneal disease.

Posner–Schlossman syndrome is characterized by recurrent episodes of markedly elevated intraocular pressure with relatively mild inflammation, but it does not typically produce the full classic picture of diffuse iris atrophy and stellate keratic precipitates.

Other causes of heterochromia include Horner syndrome and iris melanoma.

The absence of posterior synechiae despite chronic inflammation is particularly supportive of FHI.

Treatment

Inflammation

Unlike most forms of anterior uveitis, chronic low-grade inflammation in FHI often does not require topical corticosteroid therapy.

Steroid drops may have limited effect on the underlying inflammation and can increase the risk of cataract formation and steroid-induced ocular hypertension or glaucoma.

Therefore, mild asymptomatic inflammation is often observed rather than chronically treated.

If significant inflammation occurs around ocular surgery or in an atypical exacerbation, short-term corticosteroid treatment may be appropriate.

Glaucoma

Secondary glaucoma should be treated aggressively because glaucomatous optic neuropathy is an important cause of permanent visual loss.

Initial treatment usually involves standard intraocular pressure-lowering medications.

Patients with poorly controlled pressure or progressive optic nerve or visual-field damage should be referred to a glaucoma specialist.

Surgical glaucoma treatment may ultimately be necessary.

Cataract Surgery

Cataract extraction can provide substantial visual improvement when the cataract is the major cause of reduced vision.

However, surgery may be complicated by bleeding from the fragile abnormal angle vessels.

A characteristic finding is Amsler sign, in which blood appears in the anterior chamber following paracentesis or intraocular manipulation because of rupture of these abnormal vessels.

Perioperative topical corticosteroids, and occasionally systemic anti-inflammatory therapy, may be used to limit surgery-induced inflammation.

Postoperative visual outcome may still be limited by glaucoma, vitreous opacities, posterior capsule opacification, or other ocular pathology.

Vitrectomy

Pars plana vitrectomy may be considered when dense or persistent vitreous opacities cause significant visual impairment.

This is generally reserved for patients whose symptoms cannot be explained by cataract or other anterior segment abnormalities.

Referral

Patients with uncontrolled intraocular pressure, progressive optic nerve damage, or worsening visual-field loss should be referred to a glaucoma specialist.

Referral to a uveitis specialist may be useful when the diagnosis is uncertain or when the clinical presentation is atypical.

Follow-Up

Because FHI is a chronic and frequently asymptomatic disease, regular ophthalmic follow-up is essential even when the patient feels well.

The interval depends largely on the presence and severity of glaucoma and cataract.

Follow-up should include assessment of visual acuity, intraocular pressure, optic nerve status, cataract progression, anterior chamber inflammation, and vitreous opacities.

Patients with glaucoma require appropriate optic nerve imaging and visual-field monitoring.

Patient Education

Patients should understand that the disease is usually chronic but often causes little discomfort.

They should be informed that lack of pain or redness does not mean the disease is inactive or harmless, because glaucoma can progress without symptoms.

Compliance with prescribed glaucoma therapy and scheduled follow-up is particularly important.

Patients should also understand that cataract is common but is generally treatable surgically.

Prognosis

The visual prognosis is generally good when glaucoma and cataract are recognized and treated appropriately.

Many patients maintain useful vision for many years.

The most important threat to irreversible vision loss is uncontrolled secondary glaucoma, whereas cataract-related vision loss is usually reversible with surgery.

Vitreous opacities and occasional posterior segment complications can also limit final vision.

Complications

Major complications include cataract, secondary glaucoma, vitreous opacities, and occasional cystoid macular edema.

Cataract or glaucoma surgery may be complicated by intraoperative or postoperative hyphema because of abnormal angle vessels.

Permanent visual loss is most likely when glaucoma is diagnosed late or remains inadequately controlled.